Rnai composition and use thereof
By designing RNAi activators that specifically inhibit human C5 mRNA, the problems of poor safety and efficacy of existing drugs in the treatment of dry age-related macular degeneration have been solved, achieving highly efficient inhibition and prevention of C5-related diseases and reducing the risk of transformation to wet AMD.
Patent Information
- Application Number
- PCT/CN2026/094801
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-09-29
- Filing Date
- 2026-05-06
- Publication Date
- 2026-11-12
AI Technical Summary
Existing drugs for the treatment and prevention of complement protein C5-related diseases have issues with safety and efficacy in clinical applications, especially for dry age-related macular degeneration (AMD). Furthermore, existing siRNA drugs may lead to the conversion of wet AMD in patients with dry AMD.
An RNAi activator has been developed that specifically inhibits the expression of human C5 mRNA by designing a double-stranded region containing antisense and sense strands. The inhibitory efficiency is improved by utilizing complementary pairing and modification of nucleotide sequences, making it suitable for the treatment and prevention of C5-related diseases.
It achieves highly efficient inhibition of the C5 gene, providing a safe and effective solution for the treatment and prevention of C5-related diseases, especially dry age-related macular degeneration, and reduces the risk of transformation to wet AMD.
Smart Images

Figure CN2026094801_12112026_PF_FP_ABST
Abstract
Description
RNAi Compositions and Their Applications Technical Field
[0001] This disclosure relates to the field of oligonucleotide pharmaceuticals, and more specifically to RNAi compositions that inhibit complement component C5 and their applications, said RNAi compositions being used to treat and prevent symptoms and diseases associated with C5, including but not limited to age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, myasthenia gravis, immunoglobulin A nephropathy, atypical hemolytic uremic syndrome, and CHAPLE syndrome. Background Technology
[0002] Age-related macular degeneration (AMD) is a group of age-related degenerative changes in the retina and choroid of the macular region, and is one of the leading causes of irreversible blindness in the elderly worldwide (Flaxel CJ, Adelman RA, Bailey ST, et al. Age-related macular degeneration preferred practice). [J]. Ophthalmology, 2020, 127(1): P1-P65. DOI: 10.1016 / j.ophtha.2019.09.024.). The number of AMD patients worldwide is projected to reach 288 million by 2040, and the prevalence of AMD in people over 70 years of age in my country is 20.2% (Ye H, Zhang Q, Liu X, et al. Prevalence of age-related macular degeneration in an elderly urban Chinese population in China: the Jiangning eye study[J]. Invest Ophthalmol Vis Sci, 2014, 55(10): 6374-6380. DOI: 10.1167 / iovs.14-14899.). In 2013, the international Beckmann AMD classification study group classified AMD into no significant age-related changes, normal age-related changes, early AMD, intermediate AMD, and advanced AMD based on clinical manifestations. Advanced AMD is classified into geographic atrophy (GA) and neovascular AMD (exudative or wet AMD) (Ferris FL 3rd, Wilkinson CP, Bird A, et al. Clinical classification of age-related macular degeneration[J]. Ophthalmology, 2013, 120(4):844-851.DOI:10.1016 / j.ophtha.2012.10.036.). Currently, intravitreal injection of anti-VEGF drugs and laser therapy can improve visual function in patients with neovascular AMD. For dry AMD, the currently marketed drugs are Avacincaptad pegol and Pegcetacoplan, but clinical trials have shown that a certain proportion of patients with dry AMD have converted to wet AMD, failing to meet clinical needs. Therefore, there is an urgent need to develop safe and effective drugs for AMD.
[0003] Small interfering RNA (siRNA), also known as short interfering RNA or silencing RNA, is a double-stranded RNA of 20 to 25 nucleotides in length. siRNA can selectively block or cleave complementary mRNA sequences to induce post-transcriptional gene silencing, making it an important tool for validating gene function and targeting drugs in the post-genomic era.
[0004] Complement C5 is a secreted protein mainly expressed in hepatocytes. The three complement pathways—the classical pathway, the lectin pathway, and the alternative pathway—all converge at the C3 convertase. The C3 convertase produces the C5 convertase, which cleaves C5 into C5a and C5b. C5b binds to C6-C9, ultimately forming the membrane attack complex MAC (C5b-9), which induces cell lysis by forming a porous structure in the phospholipid bilayer (Alasdair W, Samir K, Sarah E, et al. Age-Related Macular Degeneration: A Disease of Systemic or Local Complement Dysregulation? [J]. Journal, Indian Academy of Clinical Medicine, 2014, 3(4). DOI: 10.3390 / jcm3041234.). Therefore, inhibiting the activity of complement protein C5 can effectively prevent or treat complement-related diseases, including but not limited to age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, myasthenia gravis, immunoglobulin A nephropathy, atypical hemolytic uremic syndrome, and CHAPLE syndrome. Currently, the representative siRNA drug targeting C5 is Cemdisiran, developed by Anlylam, which is in Phase III clinical trials.
[0005] The C5 RNAi reagent disclosed in this article is not previously disclosed or known, and provides highly efficient inhibition of C5 gene expression.
[0006] Invention Overview
[0007] This disclosure provides novel RNAi activators that inhibit C5 gene expression through RNA interference. The RNAi activators according to the present invention are suitable for the prevention and treatment of C5-related diseases or conditions such as age-related macular degeneration and paroxysmal nocturnal hemoglobinuria.
[0008] A first aspect of this disclosure provides an RNAi activator for inhibiting C5 expression, wherein the RNAi activator comprises an antisense strand and a sense strand forming a double-stranded region.
[0009] Wherein: the antisense strand comprises a nucleotide sequence complementary to at least 15 (preferably at least 16, 17, 18, 19, 20, 21, 22, or 23) consecutive nucleotides in a human C5 mRNA fragment, or a nucleotide sequence differing from said nucleotide sequence by no more than 3, 2, or 1 nucleotide; and optionally, the sense strand comprises a nucleotide sequence identical to or differing from at least 15 (preferably at least 16, 17, 18, 19, 20, or 21) consecutive nucleotides in the corresponding mRNA fragment, or a nucleotide sequence differing by no more than 3, 2, or 1 nucleotide.
[0010] The human C5 mRNA fragments mentioned therein are selected from the fragments at nucleotide positions 182-230, 749-808, 845-912, 984-1009, 1504-1530, 1884-1910 or 1979-2026 corresponding to SEQ ID NO:367.
[0011] In some embodiments, the antisense strand comprises a sequence motif comprising at least 15 (preferably at least 16, 17, 18, 19, 20, 21, 22 or 23) consecutive nucleotides of any of the antisense strands shown in Table 2, or a sequence motif differing from the sequence motif by no more than 3, 2 or 1 nucleotides.
[0012] In some embodiments, the positive strand includes a sequence motif comprising at least 15 (preferably at least 16, 17, 18, 19, 20 or 21) consecutive nucleotides of any of the positive strands shown in Table 2, or a sequence motif differing from the sequence motif by no more than 3, 2 or 1 nucleotides.
[0013] In some embodiments, the antisense strand comprises a sequence motif comprising at least 15 (preferably at least 16, 17, 18, 19, 20, 21, 22, or 23) consecutive nucleotides selected from any of the nucleotide sequences chosen from SEQ ID NO: 10, 14, 18, 20, 22, 24, 46, 72, 82, 84, 114, 130, 134, 138, 200, 222, 226, 232, 234, 236, 250, 254, 268, 328, 362, or 366) of the sequence motif, or a sequence motif differing from the sequence motif by no more than 3, 2, or 1 nucleotides.
[0014] In some embodiments, the positive strand comprises a sequence motif comprising at least 15 (preferably at least 16, 17, 18, 19, 21, 23, 45, 71, 81, 83, 113, 129, 133, 137, 199, 221, 225, 231, 233, 235, 249, 253, 267, 327, 361, or 365) consecutive nucleotides, or a sequence motif differing from the sequence motif by no more than 3, 2, or 1 nucleotides.
[0015] In some embodiments, the antisense strand comprises a sequence motif comprising at least 15 (preferably at least 16, 17, 18, 19, 20, 21, 22, or 23) consecutive nucleotides selected from any of the nucleotide sequences chosen from SEQ ID NO: 10, 14, 18, 22, 24, 72, 82, 84, 114, 130, 134, 200, 222, 226, 232, 234, 236, 250, 254, or 268, or a sequence motif differing from the sequence motif by no more than 3, 2, or 1 nucleotides.
[0016] In some embodiments, the positive strand comprises a sequence motif comprising at least 15 (preferably at least 16, 17, 21, 23, 71, 81, 83, 113, 129, 133, 199, 221, 225, 231, 233, 235, 249, 253, or 267) consecutive nucleotides, or a sequence motif differing from the sequence motif by no more than 3, 2, or 1 nucleotides.
[0017] In some embodiments, the antisense strand comprises a sequence motif comprising at least 15 (preferably at least 16, 17, 18, 19, 20, 21, 22, or 23) consecutive nucleotides selected from any nucleotide sequence of SEQ ID NO: 222, 226, 232, or 250, or a sequence motif differing from the sequence motif by no more than 3, 2, or 1 nucleotides.
[0018] In some embodiments, the positive strand includes a sequence motif comprising at least 15 (preferably at least 16, 17, 18, 19, 20, or 21) consecutive nucleotides selected from any nucleotide sequence of SEQ ID NO: 221, 225, 231, or 249, or a sequence motif differing from the sequence motif by no more than 3, 2, or 1 nucleotides.
[0019] In some embodiments, the RNAi activator includes a protruding end.
[0020] In some embodiments, the antisense strand and / or the sense strand includes a 5' overhang and / or a 3' overhang of at least one nucleotide.
[0021] In some embodiments, the antisense strand and / or the sense strand includes a 3' overhang of at least one nucleotide.
[0022] In some embodiments, the overhang is a 3' overhang consisting of 1, 2, 3, or 4 nucleotides from the 3' end of the antisense strand.
[0023] In some embodiments, the overhang is a 3' overhang consisting of two nucleotides at the 3' end of the antisense strand.
[0024] In some embodiments, the RNAi activator does not contain protrusions.
[0025] In some embodiments, the antisense strand and the sense strand each independently contain 15 to 35 nucleotides, preferably 17 to 35 nucleotides.
[0026] In some embodiments, the antisense strand contains 18 to 30 nucleotides.
[0027] In some embodiments, the antisense strand contains 19 to 25 nucleotides.
[0028] In some implementations, the positive chain contains 18 to 27 nucleotides.
[0029] In some implementations, the positive chain contains 19 to 22 nucleotides.
[0030] In some embodiments, the antisense strand and the sense strand form a double-stranded region of 15-35, 17-35, 15-30, 17-30, 15-23, 17-23, 19-35, 19-30, 19-27, 19-25, or 19-23 nucleotide pairs in length.
[0031] In some embodiments, the double-stranded region comprises 19-23 nucleotide pairs.
[0032] In some implementations, the antisense chain and the justice chain are fully or substantially complementary in the bisense region.
[0033] In some embodiments, the antisense strand is 23 nucleotides long, the sense strand is 21 nucleotides long, and the double-stranded region is 21 nucleotide pairs long.
[0034] In some embodiments, the sense and antisense strands of the RNAi activator respectively contain the sequence motifs of the sense and antisense strands of any siRNA shown in Table 2, or sequence motifs that differ from the sequence motifs of the sense and antisense strands of any siRNA shown in Table 2 by no more than 3, 2, and 1 nucleotides, respectively.
[0035] In some embodiments, the sense and antisense strands of the RNAi activator each contain the following sequence motifs, or nucleotide sequences differing from them by no more than 3, 2, or 1 nucleotide:
[0036] a1) Nucleotide sequences as shown in SEQ ID NO:9 and SEQ ID NO:10;
[0037] a2) Nucleotide sequences as shown in SEQ ID NO:13 and SEQ ID NO:14;
[0038] a3) Nucleotide sequences as shown in SEQ ID NO:17 and SEQ ID NO:18;
[0039] a4) Nucleotide sequences as shown in SEQ ID NO:19 and SEQ ID NO:20;
[0040] a5) Nucleotide sequences as shown in SEQ ID NO:21 and nucleotide sequences as shown in SEQ ID NO:22;
[0041] a6) Nucleotide sequences as shown in SEQ ID NO:23 and SEQ ID NO:24;
[0042] a7) Nucleotide sequences as shown in SEQ ID NO:45 and SEQ ID NO:46;
[0043] a8) Nucleotide sequences as shown in SEQ ID NO:71 and nucleotide sequences as shown in SEQ ID NO:72;
[0044] a9) Nucleotide sequences as shown in SEQ ID NO:81 and nucleotide sequences as shown in SEQ ID NO:82;
[0045] a10) Nucleotide sequences as shown in SEQ ID NO:83 and SEQ ID NO:84;
[0046] a11) Nucleotide sequences as shown in SEQ ID NO:113 and nucleotide sequences as shown in SEQ ID NO:114;
[0047] a12) Nucleotide sequences as shown in SEQ ID NO:129 and nucleotide sequences as shown in SEQ ID NO:130;
[0048] a13) Nucleotide sequences as shown in SEQ ID NO:133 and SEQ ID NO:134;
[0049] a14) Nucleotide sequences as shown in SEQ ID NO:137 and SEQ ID NO:138;
[0050] a15) Nucleotide sequences as shown in SEQ ID NO:199 and SEQ ID NO:200;
[0051] a16) Nucleotide sequences as shown in SEQ ID NO:221 and nucleotide sequences as shown in SEQ ID NO:222;
[0052] a17) Nucleotide sequences as shown in SEQ ID NO:225 and SEQ ID NO:226;
[0053] a18) Nucleotide sequences as shown in SEQ ID NO:231 and nucleotide sequences as shown in SEQ ID NO:232;
[0054] a19) Nucleotide sequences as shown in SEQ ID NO:233 and SEQ ID NO:234;
[0055] a20) Nucleotide sequences as shown in SEQ ID NO:235 and SEQ ID NO:236;
[0056] a21) Nucleotide sequences as shown in SEQ ID NO:249 and SEQ ID NO:250;
[0057] a22) Nucleotide sequences as shown in SEQ ID NO:253 and SEQ ID NO:254;
[0058] a23) Nucleotide sequences as shown in SEQ ID NO:267 and SEQ ID NO:268;
[0059] a24) Nucleotide sequences as shown in SEQ ID NO:327 and SEQ ID NO:328;
[0060] a25) Nucleotide sequences as shown in SEQ ID NO:361 and nucleotide sequences as shown in SEQ ID NO:362; or
[0061] a26) Nucleotide sequences as shown in SEQ ID NO:365 and SEQ ID NO:366.
[0062] In some embodiments, the sense and antisense strands of the RNAi activator contain sequence motifs as shown in any of a1)-a3), a5)-a6), a8)-a13), and a15)-a23), or nucleotide sequences differing from them by no more than 3, 2, or 1 nucleotides.
[0063] In some embodiments, the sense and antisense strands of the RNAi activator contain sequence motifs shown in any of a16)-a18) and a21), or nucleotide sequences differing from them by no more than 3, 2, or 1 nucleotides.
[0064] In some embodiments, each nucleotide in the sense strand is independently a modified or unmodified nucleotide, and / or each nucleotide in the antisense strand is independently a modified or unmodified nucleotide.
[0065] In some embodiments, the RNAi activator includes modifications on the sense strand, antisense strand, or both, including nucleoside base modifications, nucleoside sugar ring modifications, inter-nucleoside linkage modifications, or any combination thereof.
[0066] In some embodiments, the modified nucleotide is selected from one or more of the following: 2'-O-methyl modified nucleotide, 2'-fluoro modified nucleotide, 2'-deoxy modified nucleotide, 2'-O-methoxyethyl modified nucleotide, 2'-amino modified nucleotide, 2'-alkoxy modified nucleotide, phosphate thioester modified nucleotide, locked nucleotide, 2',3'-broken nucleotide, debased nucleotide, L-2'-fluoro modified nucleotide, L-2'-O-methyl modified nucleotide, L-2'-deoxyribonucleotide, threononucleotide, 4'-modified threononucleotide, glycol-modified nucleotide, reverse nucleotide, reverse 2'-O-methyl modified nucleotide, reverse 2'-deoxyribonucleotide, 5'-vinyl phosphate nucleotide.
[0067] In some embodiments, the modified nucleotide is selected from one or more of the following: 2'-deoxy modified nucleotides, 2'-fluoro modified nucleotides, 2'-O-methyl modified nucleotides, 2'-O-methoxyethyl modified nucleotides, phosphate thioester modified nucleotides, 4'-modified threonine nucleic acids, and glycol nucleic acids.
[0068] In some embodiments, the modified nucleotide is selected from one or more of the following: 2'-O-methyl modified nucleotide, 2'-fluoro modified nucleotide, 2'-deoxyribonucleotide, and 2'-O-methoxyethyl modified nucleotide.
[0069] In some embodiments, at least 50% of the nucleotides of the RNAi activator are 2'-O-methyl modified nucleotides, 2'-fluoro modified nucleotides, 2'-O-methoxyethyl modified nucleotides, and / or 2'-deoxyribonucleotides.
[0070] In some embodiments, each nucleotide in the sense strand and the antisense strand is independently selected from 2'-O-methyl modified nucleotides, 2'-fluoro modified nucleotides, 2'-O-methoxyethyl modified nucleotides, and / or 2'-deoxyribonucleotides.
[0071] In some implementations, each nucleotide in the sense strand and the antisense strand is independently selected from:
[0072] b1) Nucleotides modified with 2'-O-methyl and 2'-fluoro;
[0073] b2) 2'-deoxyribonucleotides, 2'-O-methyl modified nucleotides, and 2'-fluoro modified nucleotides; or
[0074] b3) 2'-O-methoxyethyl modified nucleotides, 2'-deoxyribonucleotides, 2'-O-methyl modified nucleotides, and 2'-fluoro modified nucleotides.
[0075] In some implementations, along the 5' to 3' direction,
[0076] c1) The nucleotides at positions 1, 2, 4, 6, 8, 12, 14, 15, 17, 19, 20 and 21 of the positive strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine.
[0077] c2) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20 and 21 of the positive strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine.
[0078] c3) The nucleotides at positions 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 15, 16, 17, 18, 19, 20 and 21 of the positive strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine.
[0079] c4) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20 and 21 of the positive strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 10 is a 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine.
[0080] c5) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20 and 21 of the positive strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 9 is a 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine.
[0081] c6) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20 and 21 of the positive strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 11 is a 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine.
[0082] c7) The nucleotides at positions 1, 2, 3, 4, 5, 6, 7, 8, 12, 14, 15, 16, 17, 18, 19, 20 and 21 of the positive strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 10 is a 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine.
[0083] c8) The nucleotides at positions 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 15, 17, 18, 19, 20 and 21 of the positive strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine.
[0084] c9) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 17, 18, 19, 20, and 21 of the positive strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 10 is a 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluoronucleotides; or
[0085] The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 21 of the positive strand described in c10) are nucleotides modified with 2'-O-methyl, the nucleotides at positions 7 and 10 are nucleotides modified with 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine.
[0086] In some implementations, along the 5' to 3' direction,
[0087] d1) The nucleotides at positions 1, 4, 6, 7, 9, 11, 12, 13, 15, 17, 19, 20, 21, 22 and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine.
[0088] d2) The nucleotides at positions 1, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22 and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine.
[0089] d3) The nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22 and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5 and 7 are nucleotides modified with 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine.
[0090] d4) The nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5 and 7 are nucleotides modified with 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluoronucleotide;
[0091] d5) The nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 12, 13, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5 and 7 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotide at position 15 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluoro.
[0092] d6) The nucleotides at positions 1, 4, 5, 7, 8, 9, 10, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 2 is a nucleotide modified with 2'-deoxyribonucleotide, the nucleotide at position 3 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluoro.
[0093] d7) The nucleotides at positions 1, 5, 7, 8, 9, 10, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 2 and 4 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotide at position 3 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluoro.
[0094] d8) The nucleotides at positions 1, 3, 4, 5, 7, 8, 9, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 12 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluoro.
[0095] d9) The nucleotides at positions 1, 3, 4, 5, 7, 8, 9, 10, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 11 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluoro.
[0096] d10) The nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22 and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 5 is a 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine.
[0097] d11) The nucleotides at positions 1, 3, 4, 8, 9, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22 and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5 and 7 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotide at position 6 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluoro.
[0098] d12) The nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 12 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotide at position 15 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluoro.
[0099] d13) The nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 16, 17, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 18 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotides at positions 12 and 15 are nucleotides modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluoro.
[0100] d14) The nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 16 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotide at position 15 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluoro.
[0101] d15) The nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 2, 5, and 7 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotide at position 15 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluoro.
[0102] d16) The nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 14 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotide at position 15 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluoro.
[0103] d17) The nucleotides at positions 1, 3, 4, 6, 8, 10, 11, 13, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 9 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotides at positions 12 and 15 are nucleotides modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluoro.
[0104] d18) The nucleotides at positions 1, 3, 4, 6, 8, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 9 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotide at position 12 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluoro.
[0105] d19) The antisense strand is composed of nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 17, 18, 19, 21, 22, and 23 that are 2'-O-methyl modified nucleotides, nucleotides at positions 5, 7, and 20 that are 2'-deoxyribonucleotides, nucleotides at positions 12 and 15 that are 2'-O-methoxyethyl modified nucleotides, and nucleotides at the remaining positions that are 2'-fluoro modified nucleotides; or
[0106] In d20), the nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 15, 17, 18, 19, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 20 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotide at position 12 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluoro.
[0107] In some implementations, along the 5' to 3' direction,
[0108] f1) The nucleotides at positions 1, 2, 4, 6, 8, 12, 14, 15, 17, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 4, 6, 7, 9, 11, 12, 13, 15, 17, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine.
[0109] f2) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine.
[0110] f3) The nucleotides at positions 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5 and 7 are nucleotides modified with 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine.
[0111] f4) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5 and 7 are nucleotides modified with 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine.
[0112] f5) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 12, 13, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5 and 7 are 2'-deoxyribonucleotides, the nucleotide at position 15 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine.
[0113] f6) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 4, 5, 7, 8, 9, 10, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 2 is a 2'-deoxyribonucleotide, the nucleotide at position 3 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine.
[0114] f7) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 5, 7, 8, 9, 10, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 2 and 4 are 2'-deoxyribonucleotides, the nucleotide at position 3 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine.
[0115] f8) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 10 is a 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 5, 7, 8, 9, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 12 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine.
[0116] f9) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 9 is a 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 5, 7, 8, 9, 10, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 11 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine.
[0117] f10) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 11 is a 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine; The nucleotides at positions 1, 3, 4, 5, 7, 8, 9, 10, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 11 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine.
[0118] f11) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 5 is a 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine.
[0119] f12) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 8, 9, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5 and 7 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotide at position 6 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine.
[0120] f13) The nucleotides at positions 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 12 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotide at position 15 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine.
[0121] f14) The nucleotides at positions 1, 2, 3, 4, 5, 6, 7, 8, 12, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 10 is a 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 16, 17, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 18 are 2'-deoxyribonucleotides, the nucleotides at positions 12 and 15 are nucleotides modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine.
[0122] f15) The nucleotides at positions 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 15, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 16 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotide at position 15 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine.
[0123] f16) The nucleotides at positions 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 15, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 2, 5, and 7 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotide at position 15 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine.
[0124] f17) The nucleotides at positions 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 14 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotide at position 15 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine.
[0125] f18) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 10 is a 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 6, 8, 10, 11, 13, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 9 are 2'-deoxyribonucleotides, the nucleotides at positions 12 and 15 are nucleotides modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine.
[0126] f19) The nucleotides at positions 1, 2, 3, 4, 5, 6, 7, 8, 12, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 10 is a 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 6, 8, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 9 are 2'-deoxyribonucleotide, the nucleotide at position 12 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine.
[0127] f20) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are 2'-O-methyl modified nucleotides, the nucleotides at positions 7 and 10 are 2'-deoxyribonucleotides, and the remaining positions are 2'-fluoro modified nucleotides; the nucleotides at positions 1, 3, 4, 6, 8, 10, 11, 13, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are 2'-O-methyl modified nucleotides, the nucleotides at positions 5, 7, and 9 are 2'-deoxyribonucleotides, the nucleotides at positions 12 and 15 are 2'-O-methoxyethyl modified nucleotides, and the remaining positions are 2'-fluoro modified nucleotides;
[0128] f21) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 10 is a 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 17, 18, 19, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 20 are 2'-deoxyribonucleotides, the nucleotides at positions 12 and 15 are nucleotides modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine.
[0129] f22) The nucleotides at positions 1, 2, 3, 4, 5, 6, 7, 8, 12, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 10 is a 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 15, 17, 18, 19, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 20 are 2'-deoxyribonucleotide, the nucleotide at position 12 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine.
[0130] f23) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are 2'-O-methyl modified nucleotides, the nucleotides at positions 7 and 10 are 2'-deoxyribonucleotides, and the remaining positions are 2'-fluoro modified nucleotides; the nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 17, 18, 19, 21, 22, and 23 of the antisense strand are 2'-O-methyl modified nucleotides, the nucleotides at positions 5, 7, and 20 are 2'-deoxyribonucleotides, the nucleotides at positions 12 and 15 are 2'-O-methoxyethyl modified nucleotides, and the remaining positions are 2'-fluoro modified nucleotides;
[0131] f24) The nucleotides at positions 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 12 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotide at position 15 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine.
[0132] f25) The nucleotides at positions 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 14 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotide at position 15 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine.
[0133] f26) The nucleotides at positions 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 15, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 16 are 2'-deoxyribonucleotides, the nucleotide at position 15 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine; or
[0134] f27) The nucleotides at positions 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 15, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 2, 5, and 7 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotide at position 15 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine.
[0135] In some embodiments, the RNAi activator comprises at least 0-3 phosphate thioesters or methyl phosphates linked together.
[0136] In some embodiments, the RNAi activator comprises at least one phosphate thioester or methyl phosphate linker.
[0137] In some embodiments, the antisense strand and the sense strand each contain 0, 1, 2, or 3 thiophosphate links at the 5' end and / or the 3' end, respectively.
[0138] In some embodiments, the RNAi activator has at least one or at least two phosphate thioester nucleotide bonds at the first five nucleotides counted from the 5' end of the antisense strand.
[0139] In some embodiments, the RNAi activator has one or two phosphate thioester nucleotide bonds at the first five nucleotides counted from the 3' end of the antisense strand.
[0140] In some embodiments, the RNAi activator has at least one or at least two phosphate thioester nucleotide bonds at the first five nucleotides counted from the 5' end of the positive strand.
[0141] In some embodiments, the RNAi activator has at least one or at least two phosphate thioester nucleotide bonds at the first five nucleotides counted from the 3' end of the positive strand.
[0142] In some embodiments, the antisense chain comprises two phosphate thioester links at the 5' end and the 3' end, respectively; and / or
[0143] The positive chain contains 0, 1, and 2 thiophosphate linkages at the 5' and 3' ends, respectively.
[0144] In some embodiments, the RNAi activator has phosphate-thioester nucleotide bonds between the first and second nucleotides and between the second and third nucleotides, counting from the 5' end of the antisense strand; and the RNAi activator has phosphate-thioester nucleotide bonds between the first and second nucleotides and between the second and third nucleotides, counting from the 3' end of the antisense strand; and / or
[0145] The RNAi activator has phosphate-thionucleotide bonds between the first and second nucleotides and between the second and third nucleotides, counting from the 5' end of the positive strand.
[0146] In some embodiments, the antisense strand of the RNAi activator comprises: a sequence motif of at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 consecutive nucleotides of any antisense strand shown in Tables 3, 6, or 8-1, or a sequence motif differing from the sequence motif by no more than 3, 2, or 1 nucleotides.
[0147] In some embodiments, the positive strand of the RNAi activator comprises: a sequence motif of at least 17, at least 18, at least 19, at least 20, or at least 21 consecutive nucleotides of any positive strand shown in Tables 3, 6, or 8-1, or a sequence motif differing from the sequence motif by no more than 3, 2, or 1 nucleotides.
[0148] In some embodiments, the antisense strand of the RNAi activator comprises: a sequence motif of at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 consecutive nucleotides of any antisense strand shown in Table A or Table B, or a sequence motif that differs from the sequence motif by no more than 3, 2, or 1 nucleotides.
[0149] In some embodiments, the positive strand of the RNAi activator comprises: a sequence motif of at least 17, at least 18, at least 19, at least 20, or at least 21 consecutive nucleotides of any positive strand shown in Table A or Table B, or a sequence motif that differs from the sequence motif by no more than 3, 2, or 1 nucleotides.
[0150] In some embodiments, the RNAi activator comprises the sense and antisense strands of any siRNA selected from those shown in Table 3, Table 6, or Table 8-1.
[0151] In some embodiments, the RNAi activator comprises the sense and antisense strands of any siRNA selected from those shown in Table A or Table B.
[0152] A second aspect of this disclosure provides an RNAi conjugate comprising an RNAi activator of the first aspect of this disclosure.
[0153] In some embodiments, the conjugation of the RNAi conjugate occurs at the 5' and / or 3' end of the sense strand of the RNAi activator and optionally at the 3' end of the antisense strand. Optionally, the conjugation is performed via thiophosphate group linkage or phosphate group linkage.
[0154] In some embodiments, the RNAi activator is conjugated with antibodies, peptides, peptide mimics, aptamers, small chemical compounds, lipids, cell-penetrating peptide polymers, or nanoparticles.
[0155] In some embodiments, the RNAi activator is conjugated to an asialic acid glycoprotein receptor (ASGPR) ligand.
[0156] In some embodiments, the ASGPR ligand comprises one or more N-acetylgalactosamine (GalNAc) or derivative thereof.
[0157] In some embodiments, the ASGPR ligand comprises monovalent, bivalent, trivalent, or tetravalent ASGPR ligands.
[0158] In some embodiments, the ASGPR ligand is selected from monovalent, divalent, trivalent, or tetravalent GalNAc ligands.
[0159] In some embodiments, the RNAi conjugate has the following structure:
[0160] M-(ON), where ON represents the oligonucleotide duplex of the RNAi activator, M represents the trivalent GalNAc ligand, and "-" indicates that the trivalent GalNAc ligand is coupled to the oligonucleotide duplex via a chemical bond or a linker group.
[0161] In some embodiments, M is attached to the 3' end of the positive strand of the RNAi activator.
[0162] In some embodiments, the trivalent GalNAc ligand has the following structure:
[0163] In some embodiments, the RNAi conjugate has the structure shown in the following formula:
[0164] in The term represents the double-stranded oligonucleotide of the RNAi, where 3' represents the 3' end of the positive strand, and X is O or S.
[0165] In some embodiments, the RNAi conjugate is selected from any of the conjugates in Table B or Table 8-2.
[0166] A third aspect of this disclosure provides a composition comprising an RNAi activator of the first aspect of this disclosure or an RNAi conjugate of the second aspect of this disclosure and optionally a pharmaceutically acceptable diluent, carrier, and / or excipient.
[0167] In some embodiments, the diluent is PBS buffer, physiological saline, or water; or
[0168] The RNAi reagent or conjugate is present in a buffer solution.
[0169] In some embodiments, the buffer solution comprises acetate, citrate, alcohol-soluble gluten, carbonate, or phosphate, or any combination thereof; more preferably, the buffer solution is phosphate-buffered saline (PBS).
[0170] A fourth aspect of this disclosure provides a pharmaceutical combination comprising an RNAi active agent of the first aspect of this disclosure, an RNAi conjugate of the second aspect of this disclosure, or a composition of the third aspect of this disclosure, and one or more other therapeutic agents, said other therapeutic agents being any therapeutic agents effective in preventing or treating diseases or conditions mediated or associated with C5.
[0171] A fifth aspect of this disclosure provides a method for inhibiting C5 gene expression in cells, wherein the method comprises delivering an RNAi activator of the first aspect of this disclosure, an RNAi conjugate of the second aspect of this disclosure, a composition of the third aspect of this disclosure, or a pharmaceutical combination of the fourth aspect of this disclosure to the cells, thereby inhibiting C5 gene expression in the cells.
[0172] In some embodiments, the cells are in vitro or isolated cells.
[0173] In some embodiments, the cells are human cells or monkey cells.
[0174] The sixth aspect of this disclosure provides the use of the RNAi activator of the first aspect of this disclosure, the RNAi conjugate of the second aspect of this disclosure, the composition of the third aspect of this disclosure, or the pharmaceutical combination of the fourth aspect of this disclosure as a medicament or in the preparation of a medicament, preferably wherein the medicament is used to reduce C5 levels and / or expression in a subject, or to prevent or treat diseases or conditions mediated or associated with C5.
[0175] In some embodiments, the disease or condition is selected from: age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, myasthenia gravis, immunoglobulin A nephropathy, atypical hemolytic uremic syndrome, CHAPLE syndrome, geographic atrophy, hemolysis, and neuromyelitis optica.
[0176] A seventh aspect of this disclosure provides a method for preventing or treating diseases or conditions mediated or associated with C5, wherein the method comprises administering to a subject in need a therapeutically effective amount of an RNAi active agent of the first aspect of this disclosure, an RNAi conjugate of the second aspect of this disclosure, a composition of the third aspect of this disclosure, or a pharmaceutical combination of the fourth aspect of this disclosure.
[0177] In some embodiments, the disease or condition is selected from: age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, myasthenia gravis, immunoglobulin A nephropathy, atypical hemolytic uremic syndrome, CHAPLE syndrome, geographic atrophy, hemolysis, and neuromyelitis optica.
[0178] Therefore, in a first aspect, the present invention provides an RNAi activator for inhibiting C5 expression, wherein the RNAi activator comprises an antisense strand and a sense strand complementary to at least a portion of the sequence in the antisense strand to form a double-stranded region, wherein: the antisense strand comprises a nucleotide sequence complementary to at least 15 (preferably at least 16, 17, 18, 19, 20, 21, 22, or 23) consecutive nucleotides in a human C5 mRNA fragment, or a nucleotide sequence differing from said nucleotide sequence by no more than 3, 2, or 1 nucleotide; and optionally, the sense strand comprises a nucleotide sequence identical to or differing from at least 15 (preferably at least 16, 17, 18, 19, 20, or 21) consecutive nucleotides in the corresponding mRNA fragment by no more than 3, 2, or 1 nucleotide.
[0179] The C5 mRNA fragments are selected from the fragments at positions 182-230, 749-808, 845-912, 984-1009, 1504-1530, 1884-1910 or 1979-2026 corresponding to SEQ ID NO:367.
[0180] In some embodiments, the present invention provides an antisense strand of an RNAi activator comprising a sequence motif comprising at least 15 (preferably at least 16, 17, 18, 19, 20, 21, 22, or 23) consecutive nucleotide bases of any nucleotide sequence selected from SEQ ID NO: 20, 46, 72, 84, 130, 138, 200, 254, 268, 328, 362, or 366; or identical to the nucleotide sequence in at least 15 consecutive nucleotide bases (preferably at least 16, 17, 18, 19, more preferably at least 20, 21, 22, or 23 consecutive nucleotide bases), or differing from the nucleotide sequence by no more than 3, 2, or 1 nucleotide base; or comprising at least 15 consecutive nucleotide bases differing from the nucleotide sequence by no more than 3, 2, or 1 nucleotide base.
[0181] Preferably, the sequence motif comprises, or is composed of, at least 15 consecutive nucleotides (preferably at least 16, 17, 18, or 19 consecutive nucleotides, and more preferably at least 20, 21, 22, or 23 consecutive nucleotides) of SEQ ID NO: 20, 46, 72, 84, 130, 138, 200, 254, 268, 328, 362, or 366, or substantially comprises thereof.
[0182] In some embodiments, the positive strand comprises a sequence motif comprising at least 15 (preferably at least 16, 17, 18, 19, 20, or 21) consecutive nucleotide bases of any nucleotide sequence selected from SEQ ID NO: 19, 45, 71, 83, 129, 137, 199, 253, 267, 327, 361, or 365; or identical to the nucleotide sequence in at least 15 consecutive nucleotide bases (preferably at least 16, 17, 18, or 19, more preferably at least 20 or 21 consecutive nucleotide bases), or differing from the nucleotide sequence by no more than 3, 2, or 1 nucleotide base; or comprising at least 15 consecutive nucleotide bases differing from the nucleotide sequence by no more than 3, 2, or 1 nucleotide base.
[0183] Preferably, the sequence motif comprises, or is composed of, at least 15 consecutive nucleotides (preferably at least 16, 17, 18, or 19 consecutive nucleotides, and more preferably at least 20 or 21 consecutive nucleotides) of SEQ ID NO: 19, 45, 71, 83, 129, 137, 199, 253, 267, 327, 361, or 365, or substantially comprises thereof.
[0184] In some embodiments, the RNAi activator according to the invention comprises an antisense strand and a sense strand forming a double helix. In some embodiments, the antisense strand comprises a sequence motif selected from the antisense strand sequences of any of the compounds in Tables 1 and 2. In some preferred embodiments, the sense strand and the antisense strand each comprise the following sequence motifs, or nucleotide sequences differing from them by no more than 3, 2, or 1 nucleotide: (1) the nucleotide sequence of SEQ ID NO:19 and the nucleotide sequence of SEQ ID NO:20; (2) the nucleotide sequence of SEQ ID NO:45 and the nucleotide sequence of SEQ ID NO:46; (3) the nucleotide sequence of SEQ ID NO:71 and the nucleotide sequence of SEQ ID NO:72; (4) the nucleotide sequence of SEQ ID NO:83 and the nucleotide sequence of SEQ ID NO:84; (5) the nucleotide sequence of SEQ ID NO:129 and the nucleotide sequence of SEQ ID NO:130; (6) the nucleotide sequence of SEQ ID NO:137 and the nucleotide sequence of SEQ ID NO:138; (7) the nucleotide sequence of SEQ ID NO:199 and the nucleotide sequence of SEQ ID NO:200; (8) the nucleotide sequence of SEQ ID NO:253 and the nucleotide sequence of SEQ ID NO:254; (9) the nucleotide sequence of SEQ ID NO:267 and the nucleotide sequence of SEQ ID NO:200. (10) The nucleotide sequence of SEQ ID NO:268; (11) The nucleotide sequence of SEQ ID NO:327 and the nucleotide sequence of SEQ ID NO:328; or (12) The nucleotide sequence of SEQ ID NO:361 and the nucleotide sequence of SEQ ID NO:362; or (13) The nucleotide sequence of SEQ ID NO:365 and the nucleotide sequence of SEQ ID NO:366.
[0185] In a second aspect, the present invention provides a modified RNAi activator, which is a modified form of the RNAi activator according to the first aspect of the present invention. The RNAi includes modifications on the sense strand, antisense strand, or both, including nucleoside base modifications, nucleoside sugar ring modifications, inter-nucleoside linkage modifications, or any combination thereof;
[0186] In some embodiments, the RNAi activator comprises at least one modified nucleotide, preferably, all or substantially all nucleotides (e.g., at least 70%, 75%, 80%, 85%, 90%, or 95% of the nucleotides) of the antisense and / or sense strands of the RNAi activator are modified nucleotides. In some embodiments, the modified nucleotide is selected from the group consisting of: 2'-O-methyl modified nucleotides, 2'-fluoro modified nucleotides, 2'-deoxy modified nucleotides, 2'-O-methoxyethyl modified nucleotides, 2'-amino modified nucleotides, 2'-alkoxy modified nucleotides, phosphate thioester modified nucleotides, locked nucleotides, 2',3'-broken nucleotides, debased nucleotides, L-2'-fluoro modified nucleotides, L-2'-O-methyl modified nucleotides, L-2'-deoxyribonucleotides, threononucleotides, 4'-modified threonanolic acid, glycol nucleotides, reverse nucleotides, reverse 2'-O-methyl modified nucleotides, reverse 2'-deoxyribonucleotides, 5'-vinyl phosphate nucleotides; and combinations thereof.
[0187] In some preferred embodiments, the modified nucleotide is selected from the group consisting of: 2'-deoxy-modified nucleotides, 2'-fluoro-modified nucleotides, 2'-O-methyl-modified nucleotides, 2'-O-methoxyethyl-modified nucleotides, phosphate-thioester-modified nucleotides, 4'-modified threonine nucleic acids, ethylene glycol nucleotides, and any combination thereof.
[0188] In some embodiments, the RNAi activator comprises a double strand with a protruding end consisting of an antisense strand and a sense strand, preferably wherein the protruding end is a 3' protrusion consisting of the last 1, 2, 3 or 4 nucleotides of the antisense strand.
[0189] In some embodiments, the length of both the antisense strand and the sense strand is between 15 and 35 nucleotides. Preferably, the antisense strand and the sense strand form a double-stranded region of 15-35, 15-30, 15-23, 19-35, 19-30, 19-25, or 19-23 nucleotide pairs. More preferably, the double-stranded region is 23-27 or 21-23 nucleotide pairs long. In some more preferred embodiments, the antisense strand is 23 nucleotides long, the sense strand is 21 nucleotides long, and the double-stranded region is 21 nucleotide pairs long.
[0190] In some embodiments, the RNAi activator comprises at least one phosphate thioester or methyl phosphate linker. In some preferred embodiments, the RNAi activator comprises 0, 1, 2, or 3 phosphate thioester links at the 5' and / or 3' ends of both the antisense and sense strands. In more preferred embodiments, the antisense strand comprises two phosphate thioester links at both the 5' and 3' ends; and / or the sense strand comprises 0, 1, or 2 phosphate thioester links at both the 5' and 3' ends.
[0191] In some embodiments, the RNAi activator comprises a 5'-terminal phosphate modification, preferably wherein the modification is a 5'-(E)-vinylphosphonate modification at the 5' end of the antisense strand, and / or a threonucleotide modification at the 5' end of the sense strand.
[0192] In some embodiments, the RNAi activator comprises a 4'-modified threonucleotide located at the 5' terminal of the positive strand, particularly having formula (A). 4'-modified threonucleotide, wherein Base represents a natural or modified nucleoside base, the natural nucleoside base being A, T, C, G or U, and wherein R represents hydrogen or an alkoxy group having 1-30 carbon atoms (e.g., 25, 23, 21, 19, 17, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 carbon atom).
[0193] In other embodiments, the RNAi activator comprises a 4'-modified threonucleotide located within the antisense and / or sense strands, particularly having formula (A). 4'-modified threonucleotides.
[0194] In some embodiments, the antisense strand of the RNAi activator of the present invention is 23 nucleotides long, wherein:
[0195] a. The antisense strand contains a 2'-fluorinated nucleotide at positions 2 and 16;
[0196] b. The 14th position of the antisense strand contains a nucleotide that is 2'-fluorinated or 2'-deoxylated;
[0197] c. The 12th position of the antisense strand contains a 2'-fluorinated nucleotide;
[0198] d. The 6th position of the antisense strand contains a 2'-fluorinated nucleotide;
[0199] e. The fifth position of the antisense strand contains a 2'-deoxy modified nucleotide, and optionally, the seventh position contains a 2'-fluoro modified or 2'-deoxy modified nucleotide;
[0200] f. The 15th position of the antisense strand contains a nucleotide modified with 2'-O-methoxyethyl;
[0201] g. The antisense strand contains a 2'-fluorinated nucleotide at positions 2, 14, and 16, and optionally, the antisense strand contains a 2'-deoxy nucleotide at positions 5, 7, and 12.
[0202] h. The 2nd, 12th and 14th positions of the antisense strand contain 2'-fluorinated nucleotides, and optionally, the 5th, 7th and 16th positions of the antisense strand contain 2'-deoxy nucleotides;
[0203] i. Positions 12, 14, and 16 of the antisense strand contain a 2'-fluorinated nucleotide; optionally, positions 2, 5, and 7 of the antisense strand contain a 2'-deoxylated nucleotide; or
[0204] j. The antisense strand contains a 2'-fluorinated nucleotide at positions 2, 12, and 16, and optionally, the antisense strand contains a 2'-deoxy nucleotide at positions 5, 7, and 14.
[0205] The positions mentioned are all calculated from the 5' end of the antisense chain.
[0206] In some embodiments, the RNAi activator of the present invention has a sense strand length of 21 nucleotides, wherein:
[0207] a. Positions 7 and 9-11 of the positive strand contain nucleotides with a 2'-fluorinated modification;
[0208] b. The 9th, 11th, and 13th positions of the positive strand contain a nucleotide with a 2'-fluorinated modification; or
[0209] c. Positions 9, 11, 13, and 16 of the positive strand contain nucleotides with a 2'-fluorinated modification;
[0210] The positions mentioned are all calculated from the 5' end of the justice chain.
[0211] In some embodiments, the antisense strand of the RNAi activator of the present invention comprises:
[0212] (i) 18-23 modified consecutive nucleotides selected from the modified antisense strand nucleotide sequence of any of the compounds listed in Tables 3, 6, or A; or
[0213] (ii) is a modified nucleotide sequence that differs from the 18-23 modified consecutive nucleotides in (i) by no more than 3, 2 or 1 nucleotides.
[0214] In other embodiments, the sense strand of the RNAi activator of the present invention comprises:
[0215] (i) 17-21 modified consecutive nucleotides selected from the modified positive strand nucleotide sequence of any of the compounds listed in Tables 3, 6, or A; or
[0216] (ii) is a modified nucleotide sequence that differs from the 17-21 modified consecutive nucleotides in (i) by no more than 3, 2 or 1 nucleotides.
[0217] In some specific embodiments, the RNAi activator of the present invention comprises a sense strand and an antisense strand, calculated from the 5' end of either the sense strand or the antisense strand.
[0218] (1) The 9th, 11th and 13th positions of the sense strand are 2'-fluorinated nucleotides, the 2nd, 14th and 16th positions of the antisense strand are 2'-fluorinated nucleotides, and the 5th, 7th and 12th positions are 2'-deoxy nucleotides.
[0219] (2) The 9th, 11th, 13th and 16th positions of the sense strand are 2'-fluorinated nucleotides, the 2nd, 12th and 14th positions of the antisense strand are 2'-fluorinated nucleotides, and the 5th, 7th and 16th positions are 2'-deoxy nucleotides.
[0220] (3) The 9th, 11th, 13th, and 16th positions of the sense strand are 2'-fluorinated nucleotides, the 12th, 14th, and 16th positions of the antisense strand are 2'-fluorinated nucleotides, and the 2nd, 5th, and 7th positions are 2'-deoxylated nucleotides; or
[0221] (4) The 9th, 11th and 13th positions of the sense strand are 2'-fluorinated nucleotides, the 2nd, 12th and 16th positions of the antisense strand are 2'-fluorinated nucleotides, and the 5th, 7th and 14th positions are 2'-deoxy nucleotides.
[0222] Preferably, in modification schemes (1)-(4), the 15th position of the antisense chain is a nucleotide modified with 2'-O-methoxyethyl.
[0223] In some more preferred embodiments, the RNAi activator of the present invention comprises a modified sense strand and a modified antisense strand of any of the compounds shown in Tables 3, 6 or A.
[0224] In some embodiments, the antisense strand of the RNAi contains a 23 bp sequence motif, and the sequence motif has a modification selected from the following:
[0225] (1)Nm-Nf-(Nm)2-Nm-Nf-Nm-(Nm)6-Nf-Nm-Nf-(Nm)7;
[0226] (2)Nm-Nf-(Nm)2-dN-Nm-dN-(Nm)4- Nf-Nm-Nf-Nm-Nf-(Nm)7;
[0227] (3)Nm-Nf-(Nm)2-dN-Nm-dN-(Nm)6-Nf-Nm-Nf-(Nm)7;
[0228] (4)Nm-Nf-(Nm)2-dN-Nm-dN-(Nm)6-Nf-N(moe)-Nf-(Nm)7;
[0229] (5)Nm-Nf-(Nm)2-dN-Nm-dN-(Nm)4-Nf-Nm-Nf-N(moe)-Nf-(Nm)7;
[0230] (6)Nm-Nf-(Nm)2-Nm-Nf-Nm-(Nm)6-Nf-N(moe)-Nf-(Nm)7;
[0231] (7)Nm-Nf-(Nm)2-dN-Nm-dN-(Nm) 4- dN-Nm-Nf-N(moe)-Nf-(Nm)7;
[0232] (8)Nm-Nf-(Nm)2-dN-Nm-dN-(Nm) 4- Nf-Nm-Nf-N(moe)-dN-(Nm)7;
[0233] (9)Nm-dN-(Nm)2-dN-Nm-dN-(Nm) 4- Nf-Nm-Nf-N(moe)-Nf-(Nm)7; or
[0234] (10)Nm-Nf-(Nm)2-dN-Nm-dN-(Nm) 4- Nf-Nm-dN-N(moe)-Nf-(Nm)7.
[0235] Wherein, N represents nucleotide, Nm represents 2'-O-methyl modified nucleotide, Nf represents 2'-fluoro modified nucleotide, dN represents deoxyribonucleic acid, and N(moe) represents 2'-O-methoxyethyl modified nucleotide.
[0236] In some embodiments, the positive strand of the RNAi contains a 21 bp sequence motif, and the sequence motif has a modification selected from the following:
[0237] (1)(Nm)6-Nf-Nm-Nf-Nf-Nf-(Nm) 10 ;
[0238] (2)(Nm)8-Nf-Nm-Nf-Nm-Nf-(Nm)8; or
[0239] (3)(Nm)8-Nf-Nm-Nf-Nm-Nf-(Nm)2-Nf-(Nm)5;
[0240] Where N represents a nucleotide, Nm represents a nucleotide modified with 2'-O-methyl, and Nf represents a nucleotide modified with 2'-fluorine.
[0241] In a third aspect, the present invention provides a conjugate of an RNAi activator. The conjugation occurs at the 5' and / or 3' end of the sense strand of the RNAi and optionally at the 3' end of the antisense strand; optionally, the conjugation is performed via thiophosphate group linkage or phosphate group linkage.
[0242] In some embodiments, the conjugate comprises an asialic acid glycoprotein receptor (ASGPR) ligand conjugate moiety. In some preferred embodiments, the ASGPR ligand comprises one or more N-acetylgalactosamine (GalNAc) or derivative moieties thereof, preferably selected from monovalent, divalent, or trivalent GalNAc or ASGPR ligands.
[0243] In a fourth aspect, the present invention provides a composition comprising an RNAi activator of the first or second aspect of the invention or an RNAi conjugate of the third aspect and optionally a pharmaceutically acceptable carrier. For example, the composition is a pharmaceutical composition and its use. The RNAi activator or the conjugate is present in a non-buffered solution, preferably saline or water; or the RNAi activator or conjugate is present in a buffered solution, preferably comprising acetate, citrate, alcohol-soluble gluten, carbonate, or phosphate, or any combination thereof, more preferably, the buffered solution is phosphate-buffered saline (PBS).
[0244] In a fifth aspect, the present invention provides a method for inhibiting the expression of the C5 gene in cells, wherein the method comprises delivering an RNAi activator according to the first or second aspect, or a conjugate according to the third aspect of the invention, or a composition according to the fourth aspect of the invention, to the cells, thereby inhibiting the expression of the C5 gene in the cells, optionally, the cells being in vitro or ex vivo cells, preferably, the cells being human cells or monkey cells.
[0245] In a sixth aspect, the present invention provides the use of the RNAi activator according to the first and second aspects, or the conjugate according to the third aspect of the invention, or the composition according to the fourth aspect of the invention, as a medicament or in a medicament. In some preferred embodiments, the medicament is used to reduce C5 levels and / or expression in a subject, or to prevent or treat diseases or conditions mediated or associated with C5. In some embodiments, the disease or condition is selected from: age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, myasthenia gravis, immunoglobulin A nephropathy, atypical hemolytic uremic syndrome, CHAPLE syndrome, geographic atrophy, hemolysis, neuromyelitis optica.
[0246] Table 1 provides examples of some representative RNAi sequence motifs according to the present invention. In Table 1, “SS” represents the sense strand, “AS” represents the antisense strand, and “C5 mRNA (NM_001735.3) location region” represents the region containing the sense strand or the antisense strand target region. In any aspect of the present invention described above, in some cases, RNAi reagents comprising the sense and antisense strand sequence motifs provided in Table 1 are more preferred.
[0247] Table 1. Sequence motifs of representative RNAi
[0248] Table A provides representative RNAi modification sequences used in embodiments of the present invention, where "SS" represents the sense strand and "AS" represents the antisense strand. siRNAs containing modified sense and antisense strands provided in Table A are more preferably used in the present invention.
[0249] Table A represents the RNAi modification sequences.
[0250] Table B provides representative RNAi conjugates used in embodiments of the present invention, where "SS" represents the sense strand and "AS" represents the antisense strand. Containing the RNAi conjugates provided in Table B is more preferred in the present invention.
[0251] Table B represents representative RNAi conjugates. Attached Figure Description
[0252] Figure 1 shows that BPR-99812568, BPR-99811310, BPR-99811123, and BPR-99811675 in Example 6 can all inhibit the expression of mouse C5 protein.
[0253] Invention Details
[0254] In this article, unless the context clearly indicates otherwise, the singular forms “a,” “one,” and “the” cover both singular and plural referents.
[0255] In this document, the terms "about" or "approximately," when referring to a measurable value (e.g., a parameter, quantity, duration, etc.), are intended to encompass both the specified value and variations relative to that specified value, such as variations of ±10%, ±5%, ±1%, or ±0.1% or less relative to the specified value, provided that such variations apply to the disclosed technical solution. It should be understood that the specific value referred to by the terms "about" or "approximately" is itself specifically and preferably disclosed.
[0256] In this document, when the terms “comprising” or “including” are used, unless otherwise specified, they also cover situations where the term comprises the mentioned elements, integers, or steps. For example, when referring to an oligonucleotide that “comprising” a specific sequence, it is also intended to cover oligonucleotides that comprise that specific sequence.
[0257] In this paper, when referring to the sequence or sequence motif of RNAi or oligonucleotides, it is characterized by the order of nucleoside bases in that sequence or sequence motif. Since the pairing between nucleoside bases A and U corresponds to the pairing between nucleoside bases A and T, in this paper, for modified RNAi molecules or oligonucleotides containing deoxynucleotide T replacing nucleotide U, the substitution position is indicated by a U base when referring to their sequence.
[0258] In this document, for clarity, unless otherwise specified, references to RNAi or oligonucleotides are intended to refer not only to the nucleoside base sequence (i.e., sequence) of the nucleotide chain that makes up the molecule, but also to any chemical modifications present thereon (if such modifications are present). Such modifications can include modifications to the phosphate backbone, nucleoside, and sugars of the nucleotide chain, as well as conjugations of the nucleotide chain to non-nucleoside compounds. Therefore, in this disclosure, as those skilled in the art will understand, “RNAi conjugate” can be considered as a specific RNAi activator having a conjugate portion modification, and accordingly, unless the context clearly indicates otherwise, references to “RNAi activator” in this disclosure also encompass “RNAi conjugate” and “conjugates containing RNAi activators.”
[0259] In this document, C5 mRNA refers to the mRNA of human complement protein 5. For example, human complement protein 5 (hC5) mRNA with the sequence shown under Genbank accession number NM_001735.3 is also abbreviated as C5 mRNA in this invention. Accordingly, unless otherwise specified herein, the term "target gene" refers to a gene capable of transcribing said human C5 mRNA, and the term "target mRNA" refers to said human C5 mRNA.
[0260] In this document, RNAi activators for targeting C5 specifically refer to RNA molecules containing double-stranded oligonucleotides capable of binding to the C5 gene mRNA sequence and reducing C5 gene expression through an RNAi mechanism, wherein the double-stranded oligonucleotides are referred to as antisense and sense strands, respectively, based on their complementarity with the target C5 gene sequence. In this document, such RNAi activators with oligonucleotide double strands are also referred to as siRNA or double-stranded RNAi. Therefore, unless explicitly excluded by the context, reference to the RNAi molecules of the present invention having oligonucleotide double strands is equivalent to reference to the siRNA or double-stranded RNAi of the present invention, and vice versa.
[0261] In this paper, the term "antisense" in relation to nucleic acid molecules refers to a nucleotide sequence containing a region complementary to the target nucleic acid. Therefore, for an RNAi molecule containing an antisense strand targeting C5, it will contain a nucleotide sequence complementary to the "sense" nucleic acid encoding the C5 protein (e.g., a nucleotide sequence complementary to the coding strand in the double-stranded DNA of the C5 gene, or a nucleotide sequence complementary to the C5 mRNA).
[0262] In this document, "target sequence" or "target gene sequence" refers to a continuous nucleotide portion in an mRNA molecule formed during transcription of a target gene (e.g., the C5 gene). The target gene sequence associated with the RNAi disclosed herein should be at least long enough to be used as a substrate for RNAi-guided nucleic acid cleavage, thereby causing a cleavage at or near the sequence location in the mRNA molecule formed by the transcription of the target gene. For example, the length of the target sequence can be, for example, 15-36 nucleotides ("nt"), or any sub-length therein. As a non-limiting example, the length of the target sequence can be 15-30 nt, 15-26 nt, 15-23 nt, 15-22 nt, 15-21 nt, 15-20 nt, 15-19 nt, 15-18 nt, 15-17 nt, 18-30 nt, 18-26 nt, 18-23 nt, 18-22 nt, 18-21 nt, 18-20 nt, 18 nt, 19-30 nt, 19-26 nt, The target sequence length is 19-23 nucleotides, 19-22 nucleotides, 19-21 nucleotides, 19-20 nucleotides, 19 nucleotides, 20-30 nucleotides, 20-26 nucleotides, 20-25 nucleotides, 20-24 nucleotides, 20-23 nucleotides, 20-22 nucleotides, 20-21 nucleotides, 20 nucleotides, 21-30 nucleotides, 21-26 nucleotides, 21-25 nucleotides, 21-24 nucleotides, 21-23 nucleotides, or 21-22 nucleotides, 21 nucleotides, 22 nucleotides, or 23 nucleotides. In some embodiments of this disclosure, the target sequence length is preferably at least 18 nucleotides, more preferably at least 19 nucleotides. In some embodiments of this disclosure, the target sequence length is about 19 to about 30 nucleotides. In some embodiments of this disclosure, the target sequence length is about 19 to about 25 nucleotides. In some embodiments of this disclosure, the target sequence length is about 19 to about 23 nucleotides. In some embodiments of this disclosure, the target sequence length is about 21 to about 23 nucleotides. In the antisense strand of RNAi, the sequence region complementary to consecutive nucleotides in the target gene sequence is also referred to herein as a "sequence motif." Based on this core sequence motif, and applying the Watson and Crick base pairing rules, those skilled in the art who read this disclosure can readily design RNAi activator molecules that specifically target C5. The antisense strand of such RNAi activators can be, for example, about 15, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, or 50 nucleotides in length. Depending on the form of the designed RNAi activator, the antisense strand sequence outside the "sequence motif," in some cases, can or can not be designed to be completely or substantially complementary to the extension of the target sequence on C5 mRNA according to the Watson and Crick base pairing rules. RNAi activators designed in this way are all aspects of this invention.
[0263] In this document, unless otherwise specified, the terms "complementarity" or "complementarity" refer to the ability of an oligonucleotide or polynucleotide containing a first nucleotide sequence to hybridize with an oligonucleotide or polynucleotide containing a second nucleotide sequence under certain conditions and form a double-stranded structure. Those skilled in the art can determine the optimal complementarity of the two sequences and the conditions used to determine this complementarity based on the final application of the hybridized oligonucleotide or polynucleotide. Therefore, in this document, when describing the base pairing between the sense and antisense strands of RNAi, or the base pairing between the antisense strand and the target sequence of RNAi, the terms "complementarity" or "complementarity" should be understood to cover not only 100% complementarity (i.e., perfect complementarity) but also cases of less than 100% complementarity, i.e., the presence of base mismatches in the complementary double-stranded nucleic acid region that do not substantially affect the RNAi's intended function. As those skilled in the art will appreciate, in double-stranded nucleic acid molecules, when a base on one strand forms a Watson-Crick base pair with a corresponding base on the other strand in a complementary manner, the bases at that position on both strands are considered to be "complementarily paired" or "matched." For example, the purine base adenine (A) is complementary to the pyrimidine base thymine (T) or uracil (U); the purine base guanine (C) is complementary to the pyrimidine base cytosine (G). Correspondingly, a "mismatch" refers to a situation in double-stranded nucleic acids where corresponding bases on one strand are not complementary to each other. However, it should be understood that nucleotides modified in the base portion of RNA nucleosides should also be considered complementary if Watson-Crick base pairing is permitted. Therefore, in this paper, nucleoside base “complementarity” encompasses Watson-Crick base pairing between unmodified and modified nucleobases (see, for example, Hirao et al. (2012) Accounts of Chemical Research, Vol. 45, p. 2055 and Bergstrom (2009) Current Protocols in Nucleic Acid Chemistry Suppl. 371.4.1).
[0264] In this document, for the purposes of this disclosure, the expression “complementary” or “complementarity” associated with double-stranded RNAi activators (such as siRNA as described herein) is preferably not less than 70%, meaning that at least 70% of the base positions in the double-stranded region formed by complementary hybridization are complementary, i.e., the number of mismatched positions in the continuous nucleotide sequence forming the double-stranded region is less than 30%. For example, for a 21-base-pair double-stranded region, not less than 70% complementarity means that the double-stranded region forms no more than 6, 5, 4, 3, 2, 1, or 0 mismatched base pairs during hybridization. Preferably, the presence of insertions and deletions is not allowed when calculating the complementarity % of the continuous nucleotide sequence in the double-stranded region. Accordingly, in this document, the expression associated with RNAi activators, “complementary (antisense) sequence” to the target sequence, or “complementary (sense) sequence” to a portion of the antisense sequence, can be “completely complementary” or “substantially complementary.” “Completely complementary” means that the two sequences have 100% complementarity. When the first sequence is referred to herein as “substantially complementary” to the second sequence, the two sequences may contain one or more, but typically no more than 30%, 20%, or 10%, mismatched base pairs in the hybridized duplex, and still retain the ability to hybridize under conditions most relevant to its final application (e.g., repressing gene expression via a RISC pathway). It should be understood here that when the two oligonucleotides of an RNAi are designed to form one or more single-stranded overhangs during hybridization, such overhangs will not be considered mismatches when determining complementarity. For example, for the purposes described herein, an RNAi comprising a 21-nucleotide sense oligonucleotide chain and a 23-nucleotide antisense oligonucleotide chain may still be considered “perfectly complementary” if the longer antisense oligonucleotide contains a 21-nucleotide sequence that is perfectly complementary to the shorter sense oligonucleotide.
[0265] In this document, the term "protrusion" is used to describe an unpaired nucleotide located at the 3' or 5' end of the double-stranded region of a double-stranded oligonucleotide. In some embodiments according to this disclosure, the protrusion is 1 to 4 nt long and preferably located at the 3' end of the antisense strand of the RNAi. Preferably, the protrusion is 2 nt long and located at the 3' end of the antisense strand of the RNAi.
[0266] In this document, a "nucleotide difference" between two nucleotide sequences refers to a change in the type of bases at the same position of the nucleotides compared to the former. For example, if a nucleotide base in the latter is A, and the corresponding nucleotide base at the same position in the former is U, C, G, or T, then a nucleotide difference at that position is considered to exist between the two nucleotide sequences. In some embodiments, replacing the nucleotide at the original position with a baseless nucleotide or its equivalent can also be considered a nucleotide difference at that position.
[0267] In this article, the nucleosides and nucleotides that make up the nucleotide chain in nucleic acid molecules (such as RNAi or siRNA molecules) may be referred to as “units” or “monomers”.
[0268] In this document, "nucleotide" refers to the structural unit of oligonucleotides and polynucleotides, and for the purposes of this disclosure, includes naturally occurring nucleotides and modified nucleotides. In nature, RNA nucleotides comprise a sugar moiety (ribose), a nucleobase moiety, and a phosphate ester group. In this document, a modified nucleotide refers to a nucleotide that, corresponding to a natural RNA nucleotide, has modifications in its sugar moiety and / or nucleobase moiety.
[0269] In this document, the term "modified nucleoside" or "nucleoside modification" refers to a modified nucleoside formed by introducing one or more sugar moieties and / or one or more (nucleo)base moieties, compared to the corresponding RNA nucleoside. Therefore, the term "modified nucleoside" may also be used interchangeably with the term "modified nucleotide." In some preferred embodiments according to this disclosure, the modified nucleoside comprises a modified sugar moieties.
[0270] In this paper, the term "nucleobase" refers to the base portion of nucleosides and nucleotides. In natural nucleic acids, nucleobases are the purine portion (e.g., adenine and guanine) and the pyrimidine portion (e.g., uracil, thymine, and cytosine) of nucleosides. In this paper, the term "nucleobase" also encompasses modified nucleobases that may differ from naturally occurring nucleobases but are functional during nucleic acid hybridization. In this case, "nucleobase" refers to naturally occurring nucleobases such as adenine, guanine, cytosine, thymidine, uracil, xanthine, and hypoxanthine, as well as non-natural variants. Descriptions of such variants can be found, for example, in Hirao et al. (2012) Accounts of Chemical Research, Vol. 45, p. 2055 and Bergstrom (2009) Current Protocols in Nucleic Acid Chemistry Suppl. 371.4.1. In some cases, the nucleobase moiety can be modified by changing the purine or pyrimidine to a modified purine or pyrimidine, such as a substituted purine or substituted pyrimidine, such as a nucleobase selected from isocytosine, pseudoisocytosine, 5-methylcytosine, 5-thiazolylcytosine, 5-propynyl-cytosine, 5-propynyl-uracil, 5-bromouracil, 5-thiazolyluracil, 2-thiouracil, 2'-thiothymine, inosine, diaminopurine, 6-aminopurine, 2-aminopurine, 2,6-diaminopurine, and 2-chloro-6-aminopurine. The nucleobase moiety can be indicated by a letter code (e.g., A, T, G, C, or U) for each corresponding nucleobase, wherein each letter may optionally include a functionally equivalent modified nucleobase. For example, in the oligonucleotides of RNAi molecules exemplified in Tables 2 and 3 of this disclosure, the nucleobase portion is selected from A, T, G, C, and U.
[0271] For naturally occurring oligonucleotides, internucleotide bonds comprise phosphate groups that form phosphodiester bonds between adjacent nucleosides. Hereinafter, the term "modified internucleotide bond" is defined as a bond that covalently links two nucleosides together, other than a phosphodiester (PO) bond. The oligonucleotide chain of RNAi according to this disclosure may contain one or more internucleotide bonds derived from natural phosphodiester modifications, also referred to herein as "phosphodiester backbone modifications." Modified internucleotide bonds contemplated according to this disclosure include, but are not limited to, thiophosphate bonds, dithiophosphate bonds, methylphosphate bonds, selenophosphate bonds, phosphoramidite bonds, etc. In some embodiments, modified internucleotide bonds can increase the stability of the oligonucleotide, such as nuclease resistance, compared to phosphodiester bonds. Nuclease resistance can be determined by incubating the oligonucleotide in serum or by using a nuclease resistance assay (e.g., snake venom phosphodiesterase (SVPD)) in a manner well known in the art. In some embodiments, preferably, the internucleotide bonds in the oligonucleotides used for the RNAi of this disclosure are phosphate thioester bonds. In some embodiments, the oligonucleotides of the sense and / or antisense strands may have one or two phosphate thioester internucleotide bonds at the 5' and / or 3' ends. In some embodiments, the nucleoside linking the oligonucleotides of the RNAi of this disclosure to non-nucleotide functional groups such as conjugates may be phosphodiester bonds, or in some cases, phosphate thioester bonds.
[0272] In this document, unless otherwise stated, the term "conjugation" refers to the covalent connection between two or more chemical moieties, each having a specific function; correspondingly, "conjugated compound" refers to a compound formed by covalently connecting these chemical moieties. Accordingly, in this document, "RNAi conjugated compound" (e.g., "siRNA conjugated compound") refers to a compound formed by covalently linking one or more chemical moieties having a specific function to an oligonucleotide chain of RNAi (such as siRNA). In this document, the specific chemical moieties covalently linked to the oligonucleotide chain of RNAi (such as siRNA), or the specific compounds that can conjugate such specific chemical moieties to RNAi via a reaction, are also referred to as "conjugated moieties." In some embodiments according to this disclosure, the conjugated moieties are non-nucleoside or non-nucleotide chemical moieties, but this does not preclude the possibility that the conjugated moieties are linked to oligonucleotides via nucleosides or nucleotides or their analogues or derivatives.
[0273] In this document, "optional" or "optionally" means that the event or condition described thereafter may or may not occur, and the description includes both the possibility that the event or condition occurs and the possibility that it does not occur. For example, "alkyl" in "optionally substituted" includes "alkyl" and "substituted alkyl" as defined below. Those skilled in the art will understand that for any group containing one or more substituents, these groups are not intended to introduce any substitution or substitution pattern that is spatially impractical, synthetically infeasible, and / or inherently unstable.
[0274] In this document, "alkyl" refers to a straight-chain or branched chain having a specified number of carbon atoms, which can be from 1 to 30 carbon atoms, for example, 1 to 20 carbon atoms, 12 to 16 carbon atoms. When referring to an alkyl residue having a specific number of carbons, it is intended to cover all branched and straight-chain forms having that number of carbons, and optionally, substitutions may be made.
[0275] In this document, "alkenyl" refers to a straight-chain or branched unsaturated hydrocarbon group having a specified number of carbon atoms and containing at least one double bond. Specifically, alkenyl groups have 2 to 20, 2 to 18, for example 2 to 6, 2 to 5, 2 to 4, or 2 to 3 carbon atoms, and are optionally substituted. For example, as used herein, the term "C2-C6 alkenyl" refers to a straight-chain or branched alkenyl group having 2 to 6 carbon atoms, such as vinyl, propenyl, allyl, 1-butenyl, 2-butenyl, 1,3-butadienyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 1,3-pentadienyl, 1,4-pentadienyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 1,4-hexadienyl, etc.
[0276] In this document, "alkynyl" refers to a straight-chain or branched unsaturated hydrocarbon group having a specified number of carbon atoms and containing at least one triple bond. Specifically, an alkynyl group has 2 to 18, for example 2 to 6, 2 to 5, 2 to 4, or 2 to 3 carbon atoms, and is optionally substituted. For example, as used herein, the term "C2-C6 alkynyl" refers to a straight-chain or branched alkynyl group having 2 to 6 carbon atoms, such as ethynyl, propynyl, propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-methyl-1-pentynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 5-methyl-2-hexynyl, etc.
[0277] In this document, the term "aryl" refers to a monocyclic or polycyclic aromatic hydrocarbon group having 6-20, for example, 6-12 carbon atoms in the ring moiety, which may be substituted or unsubstituted. Preferably, the aryl group is (C6-C6) 10Aryl group. Non-limiting examples include phenyl, biphenyl, naphthyl, or tetrahydronaphthyl, each of which may optionally be substituted with 1 to 4 substituents, such as C1-C8 or C1-C4 alkyl groups. Preferably, the aryl group is an optionally substituted phenyl group.
[0278] In this document, "heteroaryl" refers to a 5-20 membered (e.g., 5-14, 5-8, 5-6) aromatic monocyclic or polycyclic ring system containing 1-3 heteroatoms selected from N, O, or S, which may be substituted or unsubstituted. Preferably, the heteroaryl is a 5-10 membered ring system, which is a monocyclic or fused bicyclic ring. Representative heteroaryl groups include 2- or 3-thienyl, 2- or 3-furanyl, 2- or 3-pyrroleyl, 2-, 4- or 5-imidazolyl, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isooxazolyl, 3- or 5-1,2,4-triazolyl, 4- or 5-1,2,3-triazolyl, tetrazolyl, 2-, 3- or 4-pyridinyl, 3- or 4-pyrazinyl, 3-, 4- or 5-pyrazinyl, 2-pyrazinyl, 2-, 4- or 5-pyrimidinyl. Preferably, the heteroaryl group is a phenyl group containing 1 to 3 heteroatoms independently selected from N, O, and S.
[0279] In this document, "GalNAc ligand" refers to an asialic acid glycoprotein receptor (ASGPR) ligand containing a structural moiety of N-acetylgalactosamine (GalNAc) or a derivative thereof. This term encompasses monovalent, divalent, trivalent, tetravalent, and multivalent GalNAc ligands providing one, two, three, four, or more structural moieties of GalNAc or GalNAc derivatives.
[0280] In this document, the term "isolated" as a modifier for a compound means that the compound is artificially prepared or that the compound is completely or at least partially isolated from the natural environment in which it is naturally found. It should be understood that, unless otherwise stated, the compounds used in this disclosure (whether chemical or biochemical) are isolated. In some cases, the isolated compound is "purified" or "partially purified" from its production or preparation environment, and thus does not contain at least some of the components present in the environment in which the compound is produced or prepared. In some embodiments, the isolated compound has a purity of at least 90%. A "purified" or "partially purified" compound may be combined with one or more other compounds to form a composition that achieves a particular purpose. Therefore, "purified" or "partially purified" does not exclude combinations of such compositions, such as the combination of an RNAi conjugate with a second active agent for a C5-related disease or condition to be treated.
[0281] In this document, the terms “subject,” “individual,” and “patient” are used interchangeably and refer to vertebrates, preferably mammals, and more preferably humans. Mammals include, but are not limited to, primates (e.g., human and non-human primates), laboratory animals (e.g., rodents, such as mice and rats), farm animals (e.g., cattle, pigs, sheep, and horses), grazing animals, and pets (such as dogs and cats).
[0282] In this document, the term "treatment" of a symptom and / or disease in mammals means (i) prevention of the symptom or disease, i.e., avoidance of any symptoms of the disease or symptom; (ii) suppression of the symptom or disease, i.e., prevention of the occurrence or progression of symptoms; and / or (iii) relief of the symptom or disease, i.e., eliciting symptom resolution. This term encompasses both therapeutic and preventative treatments. Therefore, in some aspects, an RNAi active agent or RNAi conjugate according to this disclosure may be administered therapeutically to inhibit, reduce, relieve, stop, or reverse the progression of a C5-related disease or symptom or its symptoms in a subject, or to stabilize the development or progression of said disease or symptom or its symptoms.
[0283] In this document, the term "prevention" refers to reducing or decreasing the likelihood of a subject developing a disease or disease symptoms. Therefore, in some aspects, the RNAi active agent or RNAi composition of this disclosure may be administered prophylactically to prevent the occurrence or recurrence of C5-related diseases or conditions or their symptoms in a subject. In some aspects, the subject does not yet have, but is at risk of having, said disease or condition, or is susceptible to developing said disease or condition.
[0284] In this article, "effective amount" means a predetermined amount of active agent that can elicit a desired biological or medical response in an organization, system, animal, or human, and / or an amount that prevents, inhibits, delays, or reverses the progression of a disease state or any other adverse symptom, or otherwise improves a disease state or symptom to achieve the desired therapeutic effect.
[0285] In this document, "therapeutic effective dose" and "preventive effective dose" refer to the amount that effectively achieves the desired therapeutic or preventive outcome at the required dose and for the required duration. Therapeutic and preventive effective doses can vary depending on various factors such as the disease to be treated or prevented, the individual's age, sex, and weight. Therapeutic and preventive effective doses are amounts in which any toxic or harmful effects are less than the beneficial therapeutic / preventive effects. Compared to subjects who have not received the drug, "therapeutic effective doses" and "preventive effective doses" preferably reduce measurable parameters (e.g., serum C5 levels or serum triglyceride levels) by at least about 20%, more preferably at least about 40%, even more preferably at least about 60%, and even more preferably at least about 80%. The ability of the RNAi active agent or RNAi conjugate of this disclosure to reduce said measurable parameters can be evaluated in in vitro or animal model systems that predict therapeutic efficacy in humans. Typically, prophylactic administration is performed in subjects before the onset of disease symptoms, or before or at an earlier stage of the disease. Detailed Implementation
[0286] This disclosure provides RNAi activators (especially siRNAs with oligonucleotide double strands) that silence the C5 gene using an RNAi mechanism, conjugates thereof, compositions, and uses. In cell-based and animal studies, this disclosure has demonstrated that the siRNA molecules of this disclosure specifically and efficiently mediate RNAi, resulting in a significant inhibition of C5 gene expression. Therefore, methods and compositions comprising these siRNAs can be used to treat diseases or conditions that would benefit from downregulation of C5 expression (such as age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, and myasthenia gravis). Using these siRNAs allows for targeting of conditions that reduce intravascular hemolysis, stabilize hemoglobin levels, and / or reduce C5 mRNA expression.
[0287] The following provides a detailed description of various aspects of this disclosure. Those skilled in the art will understand that any combination of any technical features of these aspects is within the scope of this disclosure unless the context explicitly indicates otherwise. Furthermore, those skilled in the art will understand that, unless the context explicitly indicates otherwise, RNAi active agents, conjugates, compositions, methods, pharmaceuticals, and uses according to any aspect of this disclosure may include any such combination of features.
[0288] RNAi activator
[0289] In a first aspect, this disclosure provides an RNAi activator targeting C5. According to this disclosure, “RNAi” or “RNAi activator” is an activator molecule containing RNA (or a derivative thereof), wherein the activator is capable of mediating the targeted cleavage of messenger RNA (mRNA) (i.e., C5 mRNA) via the RNA-induced silencing complex (RISC) pathway.
[0290] Intrinsic RNAi (RNA interference) mechanisms in organisms typically involve a series of processes, including: Dicer processing long dsRNA into short 19-21 base pairs (bp) siRNA; siRNA binding to Ago protein to form an RNA-induced silencing complex (RISC); the AGO protein cleaving the sense strand of the siRNA and releasing it; subsequently, the mature RISC bound to the antisense strand cleaves the mRNA that is anticomplementary to the antisense strand through a sequence complementation mechanism. Based on this RNA interference mechanism, various artificial RNAi molecules with different structures have been developed. These structures can enter the RNAi pathway at different stages to achieve sequence-specific cleavage of target gene transcripts. See, for example, Molecules 2019, 24, 2211; doi:10.3390 / molecules24122211 (this literature is hereby incorporated herein by reference in its entirety for the purposes of this invention). Artificial RNAi molecules with such structures include, for example, siRNA molecules having a double-stranded region and one or two overhangs, long-chain siRNA molecules that can serve as substrates for the Dicer enzyme, short hairpin RNA (shRNA) that can be processed by Dicer to produce siRNA structures, and long single-stranded siRNA molecules containing only an antisense strand. It is understood that these molecular forms all fall within the scope of the RNAi activators disclosed herein. However, in some aspects, preferably, the RNAi activator according to this disclosure refers to an siRNA molecule containing an oligonucleotide double strand, i.e., a sense strand (sense oligonucleotide) and an antisense strand (antisense oligonucleotide), wherein the sense strand is complementary to at least a portion of the sequence of the antisense strand (e.g., at least 15, 16, 17, 18, or 19 consecutive nucleotides) to form an oligonucleotide double-stranded region. For example, siRNA molecules having a 19-21 nt double-stranded region and a 2-nt 3' overhang, or siRNA molecules containing a 20-22 nt antisense strand and a 15-16 nt short sense strand, thus having an atypical long overhang, are all within the scope of this disclosure. In addition, molecules in which the sense and antisense strands of the RNAi molecules disclosed herein are covalently linked together by a single nucleotide strand or other linkage (e.g., shRNA molecules described below) are also considered in this disclosure.
[0291] In this paper, the RNAi-related term "antisense strand" refers to an oligonucleotide chain in an RNAi activator containing a region complementary to a consecutive nucleotide of the target sequence. The RNAi-related term "sense strand" refers to an oligonucleotide chain in an RNAi activator containing a region complementary to at least a portion of the antisense strand to form a double-stranded region. In this paper, the antisense strand is sometimes also referred to as the "guide" strand, and the sense strand as the "passenger" strand.
[0292] For the purpose of inhibiting target mRNA expression, as those skilled in the art will know, the oligonucleotide used as the sense strand does not participate in direct complementary binding to the target gene, and does not need to have perfectly complementary base pairing with the antisense strand oligonucleotide in the duplex region. Therefore, in some aspects, the sense strand (passenger strand) according to this disclosure may include at least one or more of the following properties: substantially complementary to the consecutive nucleotides of the antisense strand in the duplex region with the antisense strand, for example, at least 70%, at least 80%, at least 90%, or 100% complementary; having one or more additional nucleotides forming a protrusion or loop relative to the consecutive nucleotides of the antisense strand in the duplex region; and having one or more nucleotide gaps or vacancies relative to the consecutive nucleotides of the antisense strand in the duplex region. Similarly, for the purpose of inhibiting target mRNA expression, as those skilled in the art will understand, the antisense strand serving as the guide RNAi for specific binding to the target mRNA may also contain sequences that are not 100% complementary to the continuous nucleotide regions of the target mRNA; for example, the complementarity may be at least 80%, at least 90%, or 95% complementary; however, in some cases, 100% complementarity is preferred. For the purposes of this disclosure, in some aspects, when considering the sequence motif of the antisense strand to be complementary to the continuous nucleotide regions of the target gene sequence, the presence of insertions and deletions is preferably not permitted. With regard to the sense and antisense strands of this disclosure, in some aspects, when the complementary region is not perfectly complementary to the said continuous nucleotide region, the mismatch may be located inside or at the end of that region, for example, a mismatch of 3, 2, or 1 nucleotides at the 5' and / or 3' ends.
[0293] In some embodiments, this disclosure provides an RNAi activator whose antisense strand comprises a sequence motif complementary to at least 18, at least 19, at least 20, or all consecutive nucleotides in a target gene sequence. In some embodiments, complementarity refers to at least 80% complementarity, i.e., nucleotide mismatches at no more than 20% of the positions in the consecutive nucleotide regions of the target gene sequence. In other embodiments, complementarity refers to at least 85%, 90%, or 95% complementarity. In still other embodiments, complementarity refers to 100% complementarity. In some embodiments, the target gene sequence is a completely complementary sequence of the antisense strand sequence selected from any of the compounds in Table 2, or a human C5 mRNA fragment corresponding to the sequence. The correspondence between the mRNA fragment and the specified sequence can be determined by sequence alignment. In some embodiments, this disclosure also considers the case where the sequence motif of the antisense strand is complementary to at least 18, at least 19, at least 20, or all consecutive nucleotides in a region comprising the target gene sequence and two nucleotides upstream and downstream of it. In some implementations, the length of the antisense strand is, for example, about 15, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45 or 50 nucleotides.
[0294] In some embodiments, this disclosure also provides a sense strand complementary to at least a portion of the sequence in the antisense strand according to this disclosure, and a double-stranded RNAi activator comprising such an antisense strand and a sense strand. In some embodiments, at least a portion of the sequence in the antisense strand has, for example, at least 15, 16, 17, 18, 19, 20, 21, 22, or 23 consecutive nucleotides. In some embodiments, complementarity refers to at least 70% complementarity, i.e., no more than 20% of the positions in the consecutive nucleotide region have nucleotide mismatches. In other embodiments, complementarity refers to at least 80%, 85%, 90%, 95%, or 100% complementarity. In some embodiments, the length of the sense strand is, for example, about 15, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, or 50 nucleotides.
[0295] In this document, when double-stranded RNAi and siRNA are involved, the double-stranded region formed by hybridization of the sense and antisense strands can be of any length that allows for specific degradation of C5 target mRNA via the RISC pathway. In some embodiments, this length is 15 to 36 base pairs (“bp”), or can be any length within this range, such as 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36 bp, and any subranges therein, including but not limited to 15-30 bp, 15-26 bp, 15-23 bp, 15-22 bp, 15-21 bp, 15-20 bp, 15-19 bp, 15-18 bp, 15-17 bp, 18-30 bp, 18- 26bp, 18-23bp, 18-22bp, 18-21bp, 18-20bp, 19-30bp, 19-26bp, 19-23bp, 19-22bp, 19-21bp, 19-20bp, 19bp, 20-30bp, 20-26bp, 20-25bp, 20-24bp, 20-23bp, 20-22bp, 20-21bp, 20bp, 21-30bp, 21-26bp, 21-25bp, 21-24bp, 21-23bp, 21-22bp, 21bp, 22bp, or 23bp. In some embodiments, the double-stranded RNAi and siRNA according to this disclosure have a double-stranded region of about 19 to about 30 bp. In some embodiments, the double-stranded RNAi and siRNA according to this disclosure have a double-stranded region of about 19 to about 27 bp. In some embodiments, the double-stranded RNAi and siRNA according to this disclosure have a double-stranded region of about 19 to about 25 bp. In some embodiments, the double-stranded RNAi and siRNA according to this disclosure have a double-stranded region of about 19 to about 23 bp. In some embodiments, the double-stranded RNAi and siRNA according to this disclosure have a double-stranded region of about 19 to about 21 bp. In some embodiments, the double-stranded RNAi and siRNA according to this disclosure have a double-stranded region of about 21 bp.
[0296] In some embodiments, the oligonucleotide double strands (i.e., the sense strand and the antisense strand) forming the double-stranded region in the RNAi molecule according to this disclosure need not be, but may be, covalently linked. Hereinafter, the structure is generally referred to as “shRNA” when the two strands are covalently linked by a hairpin loop. When the two strands are covalently linked by a means other than a hairpin loop, the linking structure is referred to as a “connector.” For siRNA molecules having an shRNA structure, the nucleotide single strand constituting the “hairpin loop” is located between the 3’ end of one strand forming the double-stranded structure and the 5’ end of the corresponding other strand, and may contain at least one unpaired nucleotide. In some embodiments, the hairpin loop may contain at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 20, at least 23, or more unpaired nucleotides.
[0297] In some embodiments, the double-stranded RNAi or siRNA according to this disclosure may have one or two overhangs. When the 3' end of one strand of the double-stranded oligonucleotide constituting the double-stranded RNAi or siRNA extends beyond the 5' end of the other strand, or when the 5' end of one strand extends beyond the 3' end of the other strand, unpaired nucleotides form overhangs. The length of the overhang can be at least one nucleotide; optionally, the overhang can contain at least two nucleotides, at least three nucleotides, at least four nucleotides, at least five nucleotides, or more nucleotides. The overhang can contain nucleotides or modified nucleotides, or consist of nucleotides or modified nucleosides. The overhang can be located on the sense strand, the antisense strand, or any combination thereof. Furthermore, the overhang can be located at the 5' end and / or the 3' end of the antisense strand or the sense strand. In some preferred embodiments, the RNAi according to this disclosure comprises a double-stranded body with overhangs consisting of an antisense strand and a sense strand, and preferably, the overhang is a single 3' overhang consisting of one, two, three, or four nucleotides from the terminal 3' end of the antisense strand. More preferably, the overhang is a single 3' overhang consisting of the terminal 2 nucleotides of the antisense strand. In some embodiments, the overhang on the antisense strand may be fully or substantially complementary to the extension of the target gene sequence on the C5 mRNA. In other embodiments, the overhang on the antisense strand may be non-complementary or not fully complementary to the extension of the target gene sequence on the C5 mRNA. In some embodiments, the overhang on the antisense strand has a sequence selected from 5'GU3', 5'GG3', 5'AG3', and 5'UU3', especially 5'GG3' or 5'AG3'.
[0298] The RNAi activator according to this disclosure can also have zero overhangs. In the case of zero overhangs, the RNAi activator has blunt ends, also known as a "blunt RNAi activator," and such molecules lack 3' or 5' single-stranded nucleotide overhangs.
[0299] In some embodiments, this disclosure provides an RNAi activator comprising an antisense strand and a sense strand, wherein the antisense strand and sense strand each comprise a sequence motif containing 0, 1, 2, or 3 differential nucleotides in at least 15, 16, 17, 18, 19, 20, or all consecutive nucleotides of the antisense and sense strand sequences of any of the compounds in Table 1 or Table 2. In some embodiments, the differential nucleotides are nucleotide substitutions.
[0300] In some preferred embodiments, this disclosure provides an RNAi activator comprising an antisense strand and a sense strand, wherein the antisense strand and the sense strand each comprise an antisense strand sequence and a sense strand sequence selected from any of the compounds in Table 1 or Table 2, respectively.
[0301] In some embodiments, this disclosure provides an RNAi activator comprising an antisense strand and a sense strand, wherein the antisense strand and sense strand each comprise a nucleotide sequence having a difference of no more than 3, 2, 1, or 0 nucleotides from the antisense strand and sense strand sequences of any of the following compounds; preferably, the antisense strand and sense strand each comprise the antisense strand and sense strand sequences of any of the following compounds: BPR-99803600, BPR-99806500, BPR-99818300, BPR-99813400, BPR-99816400, BPR-99818100, BPR-99810000, BPR-99806900, BPR-99804200, BPR-99801000, BPR-99812700, BPR-99802300.
[0302] In addition to the RNAi activators described above, the present invention also considers other RNAi activators that target the target gene sequences or target gene sequence regions shown in Table 1 (e.g., complementary to at least nucleotides 4 through 22 of the target gene sequence, or complementary to all nucleotides of the target gene sequence). Such RNAi activator molecules can be designed according to the Watson and Crick base pairing rules. For example, the RNAi activator can be an oligonucleotide containing a portion of the target gene sequence region antisense. Such antisense oligonucleotides can be about 5, 10, 15, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, or 50 nucleotides in length. However, in some embodiments, preferably, the RNAi activator is a double-stranded RNAi or siRNA having the characteristics described above.
[0303] In some embodiments, the RNAi of this disclosure having the aforementioned antisense and sense strands possesses one or more of the following properties: binding to the coding region of C5; not binding or hardly binding to the mRNA or transcripts of other genes (no or almost no "off-target effects"); not inducing or hardly inducing immunogenicity; capable of binding to conserved C5 mRNA sequence segments across multiple animal species (including humans, mice, rats, cynomolgus monkeys, etc.), thereby facilitating the testing of RNAi activity using experimental animals; and / or lacking specific sequences known or suspected of reducing RNAi activity. In one embodiment, the C5-specific RNAi activator according to this disclosure is a siRNA possessing any one or more of these properties.
[0304] Modification of RNAi activators
[0305] Those skilled in the art will recognize that the RNAi molecules according to this disclosure can be unmodified (i.e., containing naturally occurring RNA nucleosides), but can also be (and preferably are) modified, as long as they retain the desired functional activity (i.e., capable of forming the desired double-stranded structure and allowing or mediating specific degradation of the target RNA via the RISC pathway). Such RNA modifications can occur at the base portion, sugar portion, and / or phosphate ester linker of the nucleotide. Therefore, in a second aspect, this disclosure provides modified forms of RNAi activators according to the first aspect of this disclosure.
[0306] As a non-limiting example, modified RNAi activators can be constructed using methods known in the art, employing chemical synthesis and enzymatic ligation reactions. For instance, modified RNAi activators can be chemically synthesized using naturally occurring nucleotides or nucleotides with various modifications (designed to reduce off-target effects and / or increase the biological stability of the molecule, or to increase the physical stability of the double strand formed between antisense and sense nucleic acids).
[0307] As another non-limiting example, the oligonucleotide chain of the RNAi molecule may include at least one modified nucleoside. Alternatively, the oligonucleotide of the RNAi molecule may contain at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least fifteen, at least twenty or more modified nucleosides, or all nucleosides of the oligonucleotide may be modified nucleosides. For each of the multiple modified nucleosides in the RNAi molecule, the modification need not be identical.
[0308] In some respects, this disclosure covers modified forms of any RNAi activator specifically described herein (e.g., Table 1). In some embodiments, variants of the modifications contain the same sequence (i.e., the nucleoside base sequence) but contain modifications in the phosphate backbone, ribose, or bases. Examples of modifications that may be mentioned include, for example: 2'-O-methyl nucleotide modifications, 2'-fluoronucleotide modifications, 2'-deoxyribonucleotide modifications, locked nucleotide (LNA) modifications, unlocked nucleotide (UNA) modifications, threononucleotide (TNA) modifications, conformation-restricted nucleotide modifications, 2'-O-methoxyethyl nucleotide modifications, debased nucleotide modifications, 2'-amino nucleotide modifications, 2'-O-allyl-nucleotide modifications, 2'-C-alkyl-nucleotide modifications, 2'-O-alkyl nucleotides, morpholinonucleotides, aminophosphamide nucleotide modifications, nucleotide modifications with non-natural bases, tetrahydropyranonucleotide modifications, 1,5-dehydrated hexadiol nucleotide modifications, cyclohexenyl nucleotide modifications, nucleotide modifications containing thiophosphate groups, nucleotide modifications containing methylphosphate groups, nucleotide modifications containing 2'-phosphate groups, nucleotide modifications containing 5'-phosphate groups, thermostable nucleotide modifications, ethylene glycol nucleotide (GNA) modifications, and 2-O-(N-methylacetamide) nucleotide modifications; and combinations thereof.
[0309] In some embodiments, the RNAi activator according to this disclosure may have one or more modifications within the nucleic acid molecule or at one or both ends thereof. Examples of nucleoside base modifications, ribose moiety modifications, and phosphate backbone modifications that can be used for RNAi according to this disclosure are described below. Furthermore, a summary list of some oligonucleotide modifications known in the art can be found in PCT Publication WO 200370918. However, it is understood that the modifications that can be used for RNAi according to this disclosure are not limited thereto.
[0310] Nucleoside base modification
[0311] “G,” “C,” “A,” “T,” and “U” typically represent nucleotides containing guanine, cytosine, adenine, thymine, and uracil as bases, respectively. However, those skilled in the art will recognize that guanine, cytosine, adenine, and uracil can be replaced by other parts without substantially altering the base-pairing properties of the oligonucleotide containing the nucleotide with such a substitution. Examples of such nucleoside base modifications that can be used to generate RNAi activators include the substitution of nucleotides containing uracil, guanine, or adenine with nucleotides containing, for example, inosine; and the replacement of adenine and cytosine in oligonucleotides with guanine and uracil, respectively, to form a GU Wobble base pair with the target mRNA. In addition, other examples of modified nucleoside bases that can be used to generate RNAi activators include, but are not limited to: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl)uracil, 5-carboxymethylaminomethyl-2-thiouracil, 5-carboxymethylaminomethyluracil, dihydrouracil, β-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7 -Methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, β-D-mannosyl queosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-hydroxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-hydroxyacetic acid methyl ester, uracil-5-hydroxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl)uracil, (acp3)w, and 2,6-diaminopurine. All of these modified nucleoside bases are within the scope of consideration in this disclosure.
[0312] Sugar modification
[0313] Compared to the ribose moiety present in natural RNA, the oligonucleotides of the RNAi disclosed herein can contain one or more nucleosides with modified sugar moieties (i.e., glycosidic modifications). Numerous glycosidic modifications with ribose moieties have been developed, primarily with the aim of improving certain properties of the oligonucleotides, such as affinity and / or nuclease resistance, and off-target effects. Glycosidic modifications can include modifications by replacing the naturally occurring 2'-OH group on the ribose ring of the RNA nucleoside with other groups. Furthermore, substituents can be introduced, for example, at the 2', 3', 4', or 5' positions of the sugar ring. The following are some specific examples of 2'-modified nucleotides:
[0314] In some preferred embodiments, the RNAi activator of this disclosure comprises at least one 2'-modified nucleotide (i.e., a 2' sugar-modified nucleoside). Such modified nucleosides include nucleosides having a substituent at the 2' position other than -OH (2'-substituted nucleosides). A variety of 2'-substituted nucleosides have been developed for use in RNAi molecules, and several 2'-substituted nucleosides have been found to possess beneficial properties when incorporated into oligonucleotides. For example, 2'-modified sugars can provide oligonucleotides with enhanced binding affinity and / or increased nuclease resistance. Examples of 2'-substituted modified nucleosides are 2'-O-alkyl-RNA nucleosides, 2'-O-methyl-RNA nucleosides, 2'-alkoxy-RNA nucleosides, 2'-O-methoxyethyl-RNA nucleosides (MOE), 2'-amino-DNA nucleosides, 2'-fluoro-RNA nucleosides, and 2'-F-ANA nucleosides. Other examples can be found, for instance, in Freier and Altmann; Nucl. Acid Res., 1997, 25, 4429-4443 and Uhlmann; Curr. Opinion in Drug Development, 2000, 3(2), 293-213 and Deleavey and Damha, Chemistry and Biology 2012, 19, 937. In some embodiments, the RNAi activator according to this disclosure comprises at least one 2'-modified nucleotide. In some embodiments, the 2'-modification is selected from 2'-deoxy, 2'-fluorinated, 2'-O-methyl, 2'-O-methoxyethyl (2'-O-MOE), 2'-O-allyl, 2'-O-aminopropyl (2'-O-AP), 2'-O-dimethylaminoethyl (2'-O-DMAOE), 2'-O-dimethylaminopropyl (2'-O-DMAP), 2'-O-dimethylaminoethoxyethyl (2'-O-DMAEOE), and 2'-ON-methylacetamido (2'-O-NMA). In some embodiments, the RNAi activator according to this disclosure comprises at least one 2'-modified nucleoside selected from: 2'-O-alkyl-RNA nucleoside, 2'-O-methyl-RNA nucleoside, 2'-alkoxy-RNA nucleoside, 2'-O-methoxyethyl-RNA nucleoside (MOE), 2'-amino-DNA nucleoside, 2'-fluoro-RNA nucleoside, and 2'-F-ANA nucleoside. In some embodiments, the RNAi activator according to this disclosure comprises one or more deoxyribonucleosides.
[0315] Nucleotide analogues
[0316] In some embodiments, the RNAi activator of this disclosure comprises at least one nucleotide analog. Available nucleotide analogs include, for example, nucleotide analogs formed by replacing the ribocycle structure with one of the following: a hexose ring (HNA), a threonose ring (TNA), a glycol (GNA, an acyclic nucleotide analog formed where the pentose sugar of the nucleotide is replaced by propylene glycol), a locked nucleic acid structure (LNA, a bicyclic ring with a bimolecular bridge between the C2 and C4 carbons on the ribocycle), or a non-locked nucleic acid structure (UNA, a ribocycle lacking a bond between the C2 and C3 carbons). Other examples of available nucleotide analogs include, for example, bicyclic hexosenic nucleic acids (WO 2011 / 017521) or tricyclic nucleic acids (WO2013 / 154798); and peptide nucleic acids (PNA) or morpholino nucleic acids.
[0317] Here are some specific examples of nucleotide analogs:
[0318] In some embodiments, the RNAi activator according to this disclosure comprises at least one nucleotide analog selected from the group consisting of LNA nucleotide, UNA nucleotide, GNA nucleotide, and TNA nucleotide.
[0319] In some preferred embodiments according to this disclosure, the RNAi activator according to this disclosure comprises a 4'-modified threonucleotide as shown in formula (A). In some embodiments, the threonucleotide is located at the 5' terminal of the sense strand of the RNAi activator. In other embodiments, the threonucleotide is located within the antisense strand and / or the sense strand of the RNAi activator. For a description of 4'-modified threonucleotides that can be used in this disclosure, see the applicant's co-pending PCT application (PCT / CN2024 / 121099). This application is hereby incorporated herein by reference in its entirety for the purposes of this disclosure. In other preferred embodiments according to this disclosure, the RNAi activator according to this disclosure comprises a GNA nucleotide.
[0320] Phosphate ester backbone modification
[0321] Various phosphate backbone modifications for use in RNAi molecules are known in the art. Such modifications include, for example, thiophosphates, chiral thiophosphates, dithiophosphates, phosphate triesters, aminoalkyl phosphate triesters, methyl and other alkylphosphonates (including 3'-alkylphosphonates and chiral phosphonates), phosphonites, and aminophosphates (including 3'-aminoaminophosphates and aminoalkylaminophosphates). Furthermore, modifications to inter-nucleotide links or backbones that do not contain phosphorus atoms are also within the scope of this disclosure. A description of phosphate backbone modifications can be found in WO 2023 / 076451, which is incorporated herein by reference for the purposes of this disclosure. In some embodiments, a thiophosphate backbone modification is introduced into the nucleoside of the oligonucleotide of the RNAi molecule of this disclosure. This modification can enhance the nuclease stability of said oligonucleotide.
[0322] In some embodiments, the RNAi activator according to this disclosure may optionally also include a chemical modification at the 5' and / or 3' ends, i.e., a non-nucleotide or nucleoside chemical portion linked to the end of the oligonucleotide chain (sense and / or antisense strand) of RNAi. Examples of chemical portions linked to the 3' end of the oligonucleotide chain can be found, for example, in WO 2005 / 021749 and WO 2007 / 128477. Examples of chemical portions linked to the 5' end of the oligonucleotide chain may include, but are not limited to, a 5'-terminal phosphate ester modification, preferably said modification being selected from: 5'-(E)-vinylphosphonate (5'-(E)-VP), 5'-methylphosphonate (5'-MP), (S)-5'-C-methyl analogues, and 5'-thiophosphate (5'-PS). In some preferred embodiments, the RNAi activator according to this disclosure includes a 5'-(E)-vinylphosphonate modification at the 5' end of the antisense strand.
[0323] Exemplary modified RNAi activators
[0324] In some embodiments, this disclosure provides modified RNAi activators, particularly modified forms of RNAi activators comprising the sense and antisense strand sequences of the compounds in Table 1. In some embodiments, the modification comprises at least one phosphate backbone modification and / or at least one nucleotide modification. In some embodiments, the modification comprises at least one 2'-modified nucleotide, wherein the 2'-modification is selected from 2'-deoxy, 2'-fluoro, 2'-O-methyl, and 2'-O-methoxyethyl (2'-O-MOE). In some embodiments, the modification comprises at least one modified nucleotide selected from: 2'-O-methyl modified nucleotide, 2'-fluoro modified nucleotide, 2'-O-methoxyethyl modified nucleotide, deoxynucleoside nucleotide, UNA, LNA, GNA, and TNA (threonucleotide). In some embodiments, the TNA modification comprises a 4'-modified threonucleotide of formula (A), preferably located at the 5' end of the sense strand of the RNAi activator or within the sense and / or antisense strands.
[0325] In some preferred embodiments, the RNAi activator comprises a modified sense strand, a modified antisense strand, or preferably both a modified sense strand and a modified antisense strand of any of the compounds shown in Tables 3, 6, or 8-1.
[0326] RNAi conjugates
[0327] In a third aspect, this disclosure provides conjugate compounds formed by covalently linking an oligonucleotide double strand of RNAi according to this disclosure to a non-nucleotide portion (conjugate portion). In this document, such conjugates are also referred to as "RNAi conjugates" or "siRNA conjugates".
[0328] The conjugation of the oligonucleotide double strand of the disclosed RNAi to one or more non-nucleotide moieties can, for example, improve the pharmacological properties of the disclosed RNAi by affecting the activity, cellular distribution, cellular uptake, or stability of the oligonucleotide. In some embodiments, the conjugated moiety modulates or enhances the pharmacokinetic properties of the disclosed RNAi by improving the cellular distribution, bioavailability, metabolism, excretion, permeability, and / or cellular uptake of the oligonucleotide. In particular, the conjugation can direct the oligonucleotide to a specific organ, tissue, or cell type and thus enhance the efficacy of the disclosed RNAi in such organ, tissue, or cell type. Simultaneously, the conjugation can reduce the activity of the disclosed RNAi in non-target cell types, tissues, or organs (e.g., off-target activity or activity in non-target cell types, tissues, or organs).
[0329] Regarding the conjugate moieties and conjugation modifications applicable to RNAi, descriptions are provided in Vajinder Kumar, Targeted delivery of oligonucleotides using multivalent protein-carbohydrate interactions, Cite this: Chem. Soc. Rev., 2023, 52, 1273; Rosemary Kanasty, Delivery materials for siRNA therapeutics, NATURE MATERIALS, VOL 12, NOVEMBER 2013; Wanyi Tai, Current Aspects of siRNA Bioconjugate for In Vitro and In Vivo Delivery, Molecules 2019, 24, 2211; doi:10.3390 / molecules24122211; and WO 93 / 07883 and WO 2013 / 033230, which are incorporated herein by reference.
[0330] In some embodiments, the conjugate portion used for the RNAi active agent of this disclosure may be selected from: antibodies, peptides, peptide mimics, aptamers, small chemical compounds, lipids, cell-penetrating peptide polymers, or nanoparticle conjugates.
[0331] In some embodiments, the conjugates of this disclosure may comprise a suitable ligand-binding molecule as a conjugate portion. For example, as in International Patent Application WO 91 / 04753, oligonucleotides may be conjugated for the therapeutic administration of ligand-binding molecules that recognize cell surface molecules. The ligand-binding molecule may comprise, for example, antibodies against surface antigens, antibodies against cell surface receptors, ligands having corresponding cell surface receptors, antibodies against such ligands, or antibodies recognizing a complex of said ligand and its receptor. Methods for conjugating ligand-binding molecules to oligonucleotides are detailed in WO 91 / 04753. Additionally, conjugation methods and methods for improving cellular uptake are also described in the following International Patent Applications: WO 9640961, WO 9964449, WO 9902673, WO 9803533, WO 0015265, and U.S. Patents 5856438 and 5138045.
[0332] In some embodiments, the chemical component that can be used as a conjugate moiety is a peptide, such as a poly(L-lysine) and an antennal foot transport peptide that can significantly increase cell permeability. Such conjugates are described by Lemaitre et al., "Specific antiviral activity of a poly(L-lysine)-conjugated oligodeoxyribonucleotide sequence complementary to vesicular stomatitis virus N protein mRNA initiation site," Proc. Natl. Acad. Sci. USA, 84:648-652, 1987; U.S. Patent Nos. 6,166,089 and 6,086,900.
[0333] In other embodiments, the conjugate portion used for the RNAi active agent of this disclosure may be selected from sugars, cell surface receptor ligands, drugs, hormones, lipophilic substances, polymers, proteins, peptides, toxins (e.g., bacterial toxins), vitamins, viral proteins (e.g., capsids), or combinations thereof.
[0334] In some embodiments, for example, the conjugated moiety may include a lipid moiety, such as cholesterol (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86:6553); bile acid (Manoharan et al., Bioorg. Med. Chem. Lett., 1994, 4:1053); thioether, such as hexyl-S-triphenylmethylthiol (Manoharan et al., Ann. NY Acad. Sci., 1992, 660:306; Manoharan et al., Bioorg. Med. Chem. Let., 1993, 3:2765); thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20:533); an aliphatic chain, such as dodecyl glycol or undecyl residue (Saison-Behmoaras et al., EMBO). J., 1991, 10:111; Kabanov et al., FEBS Lett., 1990, 259:327; Svinarchuk et al., Biochimie, 1993, 75:49); phospholipids, such as di-hexadecyl-racemic-glycerol or triethylammonium 1,2-di-O-hexadecyl-racemic-glycerol-3-H-phosphate (Manoharan et al., Tetrahedron Lett., 1995, 36:3651; Shea et al., Nucl. Acids Res., 1990, 18:3777); polyamines or polyethylene glycol chains (Manoharan et al., Nucleosides & Nucleotides, 1995, 14:969) or adamantaneacetic acid (Manoharan et al., Tetrahedron Lett., 1993, 75:49); Lett., 1995, 36:3651); palmitic moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264:229) or octadecylamine or hexano-carbonyloxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277:923). In some embodiments, cholesterol conjugates are preferred because this moiety can enhance targeting to hepatocytes (the site of C5 expression).
[0335] In some embodiments, the conjugation moiety is or comprises a sugar moiety. The sugar conjugation moiety includes, but is not limited to, galactose, lactose, N-acetylgalactosamine, mannose, and mannose-6-phosphate. Sugar conjugations can be used to enhance delivery or activity in a range of tissues such as the liver and / or muscle. See, for example, EP 1495769, WO 99 / 65925, Yang et al., Bioconjug Chem (2009) 20(2):213-21; Zatsepin and Oretskaya Chem Biodivers. (2004) 1(10):1401-17.
[0336] In other embodiments, preferably, the conjugated moiety of the RNAi active agent of this disclosure is a compound moiety capable of binding to the desialyl glycoprotein receptor (ASGPR). For example, monovalent, divalent, and trivalent N-acetylgalactosamine and its derivatives conjugated moieties are all suitable for binding to ASGPR and are therefore applicable to this disclosure. For examples of ASGPR-targeting conjugated moieties, see WO2014 / 076196, WO 2014 / 207232, and WO 2014 / 179620 (these documents are incorporated herein by reference). Such conjugations can be used to enhance hepatic uptake of RNAi oligonucleotides while reducing their presence in the kidneys, thus increasing the liver / kidney ratio of the conjugated oligonucleotide compared to the same unconjugated form. Such oligonucleotide conjugates and their synthesis can also be found in the following literature: Manoharan’s comprehensive review, cited in Antisense Drug Technology, Principles, Strategies, and Applications, ed. STCrooke, Chapter 16, Marcel Dekker, Inc., 2001 and Manoharan, Antisense and Nucleic Acid Drug Development, 2002, 12, 103, each of which is incorporated herein by reference in its entirety.
[0337] In some embodiments, the conjugate moiety is attached to the 5' and / or 3' terminal nucleotide of the sense strand of the RNAi disclosed herein, and optionally the 3' terminal nucleotide of the antisense strand, optionally linked by a thiophosphate group or a phosphate group. In some cases, the conjugate moiety may also be conjugated to the internal sequence of the RNAi oligonucleotide. In some embodiments, the conjugate moiety may be attached to a phosphate group, a 2′-hydroxyl group, or a base of the nucleotide. In other embodiments, the conjugate moiety may be attached to a 3′-hydroxyl group of the nucleotide, in which case the nucleotides are linked by a 2′-5′ phosphodiester bond. When the conjugate moiety is attached to the end of an RNAi (such as siRNA) oligonucleotide chain, the conjugate moiety is typically attached to a phosphate group of the nucleotide; when the conjugate moiety is attached to the internal sequence of an RNAi (such as siRNA) oligonucleotide, the conjugate moiety is typically attached to a sugar ring of the ribose or a base.
[0338] The conjugate moiety can be directly linked to the oligonucleotide duplex of the RNAi disclosed herein or linked via a linker portion (e.g., a adapter). In some embodiments of this disclosure, the RNAi conjugate may optionally include a linker region located between the oligonucleotide duplex of the RNAi and the conjugate moiety. In some embodiments, the linker is a biocleavable linker. Such a linker typically contains or is composed of physiologically unstable bonds that are cleavable under normal in vivo conditions in mammals or under conditions similar to those in mammals. These conditions include conditions present in mammalian cells or similar chemical conditions, such as pH, temperature, oxidative or reducing conditions, or concentrations of substances and salts. These conditions also include enzymatic activities normally present in mammalian cells, such as those from proteases, hydrolases, or nucleases. In some embodiments, the linker need not be biocleavable, but may have the primary function of covalently linking the conjugate moiety to the oligonucleotide. Such a linker may comprise repeating units, such as ethylene glycol units, amino acid units, or aminoalkyl chain structures or oligomers. For example, the linker can be an aminoalkyl group, such as a C2-C36 aminoalkyl group, including C6 to C12 aminoalkyl groups. In some embodiments, conjugates having such linkers can be separated from RNAi oligonucleotides by processing with the Dicer enzyme.
[0339] In some embodiments, the adapter may include a branching region. Hereinafter, the term "branching region" means a compound portion capable of covalently coupling two or more entities together. In some embodiments, adapters having branching regions can be used to conjugate multiple entities, such as N-acetylgalactosamine moieties, to oligonucleotides of the RNAi disclosed herein. Adapters with branching regions that can be used for this purpose are known in the art and include, but are not limited to, amino acids (including natural and non-natural amino acids), peptides and their derivatives, sugar units and their derivatives, aromatic-substituted compounds and their derivatives, substituted hydrocarbon groups and their derivatives, triazole-containing derivatives, etc. See, for example, CN104651408A, CN113286888A, WO2015 / 173208, and WO2023 / 076451.
[0340] Exemplary desialyl glycoprotein receptor (ASGPR) ligand conjugates
[0341] In one embodiment of this disclosure, the oligonucleotide duplex of the RNAi of this disclosure is preferably conjugated to a conjugation moiety that can be used to deliver the oligonucleotide duplex to the liver of a subject, for example, to increase the uptake of the oligonucleotide duplex by hepatocytes. ASGP-R is a hepatocyte-specific endocytic receptor that specifically recognizes and binds to ligand molecules having galactose or galactose derivatives as terminal glycosyl groups. It has been shown that galactose derivative modifications can be used to construct drug carriers that deliver drugs to hepatocytes via ASGP-R-mediated endocytosis. Therefore, in some embodiments, the conjugation moiety for the RNAi of this disclosure comprises an ASGP-R targeting moiety (also referred to herein as an "ASGPR ligand"). The ASPG-R targeting moiety can be selected from galactose, galactosamine, N-formylgalactosamine, N-acetylgalactosamine (GalNAc), N-propionylgalactosamine, N-butyrylgalactosamine, N-isobutyrylgalactosamine, and other galactose derivatives. In this document, the term "galactose derivative" includes galactose and galactose derivatives with an affinity for ASPG-R equal to or greater than that for galactose. Preferred galactose derivatives are N-acetylgalactosamine (GalNAc) or GalNAc derivatives. Other sugars with affinity for desialyl glycoprotein receptors may also be used, including but not limited to galactosamine, N-butyrylgalactosamine, and N-isobutyrylgalactosamine. The affinity of many galactose derivatives for desialyl glycoprotein receptors has been studied (see, for example, Jobst, ST and Drickamer, K. JB. C. 1996, 271, 6686) or using methods common in the art.
[0342] In some embodiments, the ASGPR ligand constituting the conjugate moiety is monovalent, containing a single targeting moiety capable of binding to ASGPR. In other embodiments, the ASGPR ligand constituting the conjugate moiety is polyvalent, containing multiple targeting moieties capable of binding to ASGPR. In some embodiments, the ligand is a monovalent galactose ligand, providing a single galactose derivative capable of serving as an ASGPR targeting moiety. In some embodiments, the ligand is a polyvalent galactose ligand, providing multiple galactose derivatives capable of serving as ASGPR targeting moieties. Hereinafter, when the galactose derivative is N-acetylgalactosamine (GalNAc) or a GalNAc derivative, the ligand is also referred to as a GalNAc ligand, for example, providing one, two, three, or four GalNAc or GalNAc derivative structural moieties, in a monovalent, divalent, trivalent, or tetravalent manner.
[0343] In some embodiments, after the siRNA molecule according to this disclosure forms an siRNA conjugate with a conjugation portion containing a galactose derivative (e.g., GalNAc) as a targeting group, the molar ratio of the siRNA molecule to the galactose derivative (e.g., GalNAc) in the siRNA conjugate can be any suitable ratio, such as 1:1, 1:2, 1:3 or 1:4.
[0344] In some embodiments, the conjugation portion is a monovalent ASGPR ligand comprising a single terminal galactose derivative sugar moiety capable of binding to ASGPR. In other embodiments, the conjugation portion is a polyvalent ASGPR ligand comprising a galactose cluster, such as a divalent, trivalent, or tetravalent ligand, wherein the galactose cluster may contain, for example, two, three, or four terminal galactose derivative sugar moieties capable of binding to ASGPR.
[0345] In this document, a galactose cluster refers to a molecule having multiple, for example, two to four, terminal galactose derivatives. For example, a preferred galactose cluster has three terminal galactosamines or galactosamine derivatives, each exhibiting an affinity for ASGPR, wherein the terminal galactose derivatives are linked to the molecule via their C-1 or C-6 carbons. Such galactose clusters are also referred to in the art as tri-antennatic galactoses, trivalent galactoses, and galactose trimers. It is known that tri-antennatic galactose derivative clusters can bind to ASGP-R with a greater affinity than binary or monoantennatic galactose derivative structures (Baenziger and Fiete, 1980, Cell, 22, 611-620; Connolly et al., 1982, Biol. Chem., 257, 939-945).
[0346] In some embodiments, the galactose cluster to be conjugated with the oligonucleotide may comprise two or preferably three galactose derivatives respectively linked to a central branch point. In some embodiments, the galactose derivatives are preferably linked to the branch point by means of a linker or spacer group. In some embodiments, the preferred spacer group is a flexible hydrophilic spacer group (US Patent 5,885,968; Biessen et al., J. Med. Chem. 1995, Vol. 39, pp. 1538-1546). A preferred flexible hydrophilic spacer group is a PEG spacer group. A preferred PEG spacer group is a PEG3 spacer group (three ethylene units). In some aspects, the branch point can be any small molecule that allows the conjugation of the two or three galactose derivatives and further allows the branch point to conjugate to the oligonucleotide. An exemplary branch point group is dilysine. A dilysine molecule contains three amino groups that can be linked to three galactose derivatives and a carboxyl reactive group that can be linked to the oligonucleotide. Another exemplary branch point group is a tetravalent linker based on trihydroxyalkylmethane, such as a tetravalent linker based on trihydroxymethylmethane with the following structure:
[0347] The linking group comprises three oxygen groups that can be linked to three galactose derivatives and a central branching carbon atom that can be linked to an oligonucleotide. In some embodiments, each galactose derivative (sugar moiety, such as GalNAc) in the galactose cluster can be linked to the oligonucleotide via a linker, such as a polyethylene glycol (PEG) linker, such as two, three, four, five, or six PEG linkers. In this case, the linker, such as the PEG portion, can form a spacer group between the sugar moiety of the galactose derivative and the branching group. See, for example, WO2015 / 173208.
[0348] In other embodiments, the sugar moiety (e.g., GalNAc) or sugar-connector moiety (e.g., sugar-PEG moiety) to be conjugated with the oligonucleotide may also be covalently linked (conjugated) to the oligonucleotide by means of a branching group or branching region, such as an amino acid or peptide suitably containing two or more amino groups (e.g., 3, 4, or 5), such as lysine, dilysine, trilysine, or tetralysine. In some embodiments, the trilysine molecule is optionally provided with four amino groups that can thereby connect a sugar conjugation group such as a galactose derivative (e.g., GalNAc) and a carboxyl reactive group that can thereby connect the trilysine to the oligonucleotide. In other embodiments, other conjugation moieties, such as lipophilic / hydrophobic moieties, may also be linked to the oligonucleotide via the aforementioned lysine residues.
[0349] In other embodiments, the galactose cluster to be conjugated with the oligonucleotide comprises a peptide linker connected to the oligonucleotide via a bimodal linker, such as a Tyr-Asp(Asp) tripeptide or an Asp(Asp) dipeptide. Furthermore, alternative branching molecules may be selected from 1,3-bis-[5-(4,4'-dimethoxytriphenylmethoxy)pentylamino]propyl-2-[(2-cyanoethyl)-(N,N-diisopropyl)]phosphorimide (Glen Research catalog number: 10-1920-xx), tri-2,2,2-[3-(4,4'-dimethoxytriphenylmethoxy)propoxymethyl]ethyl-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphorimide (GlenResearch catalog number: 10-1922-xx), tri-2,2,2-[3-(4,4'-dimethoxytriphenylmethoxy)propoxymethyl]methyleneoxypropyl-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphorimide and 1-[5-(4,4'-dimethoxy-triphenylmethoxy)pentylamide]-3-[5-fluorenmethoxy-carbonyl-oxy-pentylamide]-propyl-2-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphorimide (Glen Research catalog number: 10-1925-xx). WO2014 / 179620 and European application number 14188444.5 describe the generation of various GalNac conjugate moieties (these documents are hereby incorporated by reference).
[0350] In some embodiments, the linking (conjugation) of the branch point to the oligonucleotide can be achieved via a linker or a spacer group. In some cases, the spacer group can be a flexible hydrophilic spacer. An example of such a flexible hydrophilic spacer group is a PEG spacer group or a C6 linker. In this case, a preferred spacer group is a PEG3 spacer group (three ethylene units). In other cases, the spacer group can be a linking group containing an N-acylpyrrolidine, such as the following linking portion:
[0351] In the embodiments involving galactose derivatives described above, in some aspects, preferably, the conjugate moiety according to this disclosure comprises GalNAc (N-acetylgalactosamine) or a derivative thereof as an ASGPR ligand, such as a monovalent, divalent, trivalent, or tetravalent GalNAc ligand. Such a GalNAc conjugate moiety can be used to target the RNAi compounds of this disclosure to the liver.
[0352] In some embodiments, the RNAi conjugate according to this disclosure comprises one or more GalNAc or GalNAc derivatives. The GalNAc or GalNAc derivative can be attached to the oligonucleotide of the RNAi via a linker, such as a divalent, trivalent, or tetravalent branched linker. In some embodiments, the GalNAc conjugate portion binds to the 3' end of the sense strand of the RNAi. In some embodiments, preferably, the GalNAc conjugate portion is attached to the 3' end of the sense strand of the RNAi oligonucleotide via the linker. In some embodiments, the GalNAc conjugate portion binds to the 5' end of the sense strand. In some embodiments, preferably, the GalNAc conjugate portion is attached to the 5' end of the sense strand of the RNAi oligonucleotide via the linker. In some embodiments, the GalNAc conjugate portion binds to the 3' end of the antisense strand. In some embodiments, preferably, the GalNAc conjugate portion is attached to the 3' end of the antisense strand of the RNAi oligonucleotide via the linker.
[0353] In some embodiments, GalNAc or a GalNAc derivative is linked to the RNAi active agent of this disclosure via a bivalent adapter. In other embodiments of this disclosure, GalNAc or a GalNAc derivative is linked to the RNAi active agent of this disclosure via a trivalent adapter. In still other embodiments of this disclosure, GalNAc or a GalNAc derivative is linked to the RNAi active agent of this disclosure via a tetravalent adapter.
[0354] In some embodiments, the RNAi conjugates of this disclosure comprise a single GalNAc or GalNAc derivative attached to a double-stranded RNAi. Preferably, the single GalNAc or GalNAc derivative is attached to the 5' or 3' end of the positive strand of the double-stranded RNAi via a linker.
[0355] In some embodiments, the RNAi conjugates of this disclosure comprise multiple (e.g., 2, 3, 4, 5, or 6) GalNAc or GalNAc derivatives. In some cases, one or more of the GalNAc or GalNAc derivatives may be individually linked to the RNAi oligonucleotide via a linker, independently of any other GalNAc or GalNAc derivative. In other cases, any two or more of the GalNAc or GalNAc derivatives may be linked to the RNAi oligonucleotide in a tandem cluster via a common linker portion. Furthermore, RNAi conjugates comprising multiple GalNAc or GalNAc derivatives linked thereto individually and / or in a tandem cluster are also within the scope of this disclosure. In some embodiments, two GalNAc or GalNAc derivatives are linked in tandem to one end (5' or 3') of the positive strand of the double-stranded RNAi, and one GalNAc or GalNAc derivative is independently linked to the other end (3' or 5') of the positive strand of the double-stranded RNAi. In other embodiments, two GalNAc or GalNAc derivatives are independently linked to the two ends of the sense strand of the double-stranded RNAi, and optionally, the double-stranded RNAi may also include one GalNAc or GalNAc derivative linked to the 3' end of the antisense strand. In other embodiments, three GalNAc or GalNAc derivatives are linked in tandem to one end (5' or 3' end) of the sense strand of the double-stranded RNAi.
[0356] In some embodiments, this disclosure provides RNAi conjugates comprising a conjugate moiety linked to an RNAi double-stranded oligonucleotide of this disclosure, wherein the conjugate moiety comprises a galactose ligand having the structure shown below:
[0357] Wherein, L represents a linker with or without a branching region, and (Gal)n represents n terminal galactose derivatives attached to the linker, wherein n is preferably 1-4, and the wavy line on the right indicates that the L portion is directly or via an additional linker to the oligonucleotide of the RNAi. In the embodiments described, the branching region may be dianticular, trianticular, or other multi-branched shapes. In some preferred embodiments, Gal represents GalNAc or a GalNAc derivative.
[0358] In some embodiments, the galactose ligand has the following structure:
[0359] Where n is an integer from 1 to 4, preferably 1, 2, or 3; L AThis indicates the use of galactose derivatives (Gal) to link L B Partial linker, L B It indicates a 2-4 valent linker based on monohydroxymethylmethane, dihydroxymethylmethane, or trihydroxymethylmethane, wherein the L... B via oxygen atoms and each of the L A Partially linked via ether bonds and attached to the RNAi oligonucleotide via a methane carbon atom (preferably via a linker). In some embodiments, preferably, the galactose ligand has the following structure:
[0360] Among them Gal and L A As defined above, and the Gal is connected to the L via the C1 oxygen atom of galactose. A Some are linked by ether bonds.
[0361] In the above-described galactose ligand embodiments, in some preferred aspects, the L... A The linker has the following structure, where the wavy line on the left indicates a connection to a galactose derivative (Gal) via the oxygen atom at the C1 position of the galactose, and the wavy line on the right indicates a connection to the aforementioned L... B Partial connection.
[0362] In the above-described galactose ligand embodiments, in some preferred aspects, the L... B Partially connected via base L C Linked to oligonucleotides. In some embodiments, the L... C This represents a connection base with the following structure, where the wavy line on the left indicates a connection with L. B Partial methane carbon atoms (i.e., branch point carbon atoms) are connected, and the wavy line on the right indicates a connection to an oligonucleotide (e.g., connected to siRNA via a phosphodiester bond or a phosphothiodiester bond):
[0363] In the above-described galactose ligand embodiments, preferably, Gal represents GalNAc or a GalNAc derivative.
[0364] In some embodiments, this disclosure provides RNAi conjugates having the following structures:
[0365] M-(ON), where ON represents the oligonucleotide duplex of the RNAi, M represents the trivalent GalNAc ligand, and "-" indicates that the trivalent GalNAc ligand is chemically coupled to the oligonucleotide duplex or coupled to a linker group; preferably, M is attached to the 3' end of the positive strand of the RNAi, wherein the conjugate portion comprises a trivalent GalNAc ligand having the following structure:
[0366] In some embodiments, this disclosure provides RNAi conjugates comprising a conjugate moiety linked to an RNAi oligonucleotide of this disclosure, wherein the conjugate moiety has an L96 structure as shown below:
[0367] The wavy line on the right indicates the connection to the siRNA oligonucleotide chain, preferably via a phosphodiester bond or a thiophosphate diester bond.
[0368] In some embodiments, the RNAi conjugates disclosed herein have the following structures:
[0369] in The term represents the double-stranded oligonucleotide of the RNAi, where 3' represents the 3' end of the positive strand, and X is O or S; the preferred conjugates of this disclosure are selected from any conjugate in Table B or Table 8-2.
[0370] Delivery of RNAi activators
[0371] The RNAi active agents and RNAi conjugates of this disclosure can be delivered or introduced by any means known in the art (e.g., to cells in vitro, to test animals, or to humans). In some embodiments, the RNAi active agents or RNAi conjugates of this disclosure are delivered to a subject, the delivery of which enables the RNAi to hybridize with cellular mRNA encoding C5 and suppress expression by inhibiting transcription. Examples of routes for delivering the RNAi active agents include direct injection at a tissue site. Alternatively, the RNAi active agents can be modified to target selected cells and then administered systemically. For example, for systemic administration, the RNAi molecules can be modified to specifically bind to a receptor or antigen expressed on the surface of selected cells, for example, by forming the aforementioned RNAi conjugates according to this disclosure that target hepatocytes, for example, by conjugating the oligonucleotide duplex of the RNAi to a peptide or antibody that binds to a receptor on the surface of hepatocytes, for example, by conjugating an ASGPR ligand according to this disclosure. The nucleic acid molecules of this disclosure can also be delivered to cells using vectors generally known in the art and described, for example, US20070111230 (the entire contents of which are incorporated herein by reference).
[0372] In this document, when referring to RNAi active agents, “delivery to cells” means assisted or facilitated uptake or absorption into cells, as understood by those skilled in the art. Absorption or uptake of RNAi active agents can occur through unassisted diffusive or active cellular processes, or through the use of an auxiliary active agent or device. The term is not limited to cells in vitro; RNAi active agents can also be “delivered to cells,” where the cells are part of a living organism. In such cases, introduction into cells will include delivery to the organism. For example, for in vivo delivery, RNAi active agents can be injected into tissue sites or administered systemically. In vivo delivery can also be performed using β-glucan delivery systems, such as those described in U.S. Patent Nos. 5,032,401 and 5,607,677 and U.S. Publication No. 2005 / 0281781. In vitro introduction into cells includes methods known in the art, such as electroporation and lipid transfection. Other means are described herein or are known in the art. Mechanisms for delivering RNAi active agents to target cells have been proposed. Methods known in the art include, but are not limited to: viral delivery (retroviruses, adenoviruses, lentiviruses, baculoviruses, AAVs); liposomes (Lipofectamine, cationic DOTAP, neutral DOPC) or nanoparticles (cationic polymers, PEI); bacterial delivery (tkRNAi); and chemical modification of siRNA (LNA) to increase stability. Xia et al., 2002 Nat. Biotechnol. 20 and Devroe et al., 2002 BMC Biotechnol. 21:15 disclose the incorporation of siRNA into viral vectors. Other systems for delivering RNAi active agents are considered, and the RNAi active agents disclosed herein can be delivered by a variety of methods pending discovery and / or approval by the FDA or other regulatory agencies. The RNAi active agents of this disclosure can be delivered in suitable pharmaceutical compositions.
[0373] Pharmaceutical compositions of RNAi activators
[0374] As used herein, a “pharmaceutical composition” includes a pharmaceutically effective amount of one or more C5 RNAi activators (especially the RNAi conjugates of the present invention), a pharmaceutically acceptable carrier, and, optionally, other therapeutic agents that synergize with the RNAi activator. As used herein, “pharmaceuticalally effective amount,” “therapeutically effective amount,” or simply “effective amount” refers to an amount of RNAi activator that effectively produces the desired pharmacological, therapeutic, or preventative outcome. For example, a given clinical treatment is considered effective if a measurable parameter associated with a disease or condition is reduced by at least 10%, and the therapeutically effective amount of a drug used to treat said disease or condition is the amount necessary to produce a reduction of at least 10% in said parameter. In this embodiment, a therapeutically effective amount of a C5-targeting RNAi activator can reduce serum C5 protein levels or serum triglyceride levels by at least 10%. In other embodiments, a given clinical treatment is considered effective when a measurable parameter associated with a disease or condition exhibits a reduction of at least 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, or 95%, and the therapeutically effective amount of the drug used to treat said disease or condition is the amount necessary to produce a reduction of at least 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, or 95%, respectively. The term "drug-approved carrier" refers to a carrier for administering a therapeutically active agent. Such carriers include, but are not limited to, saline, buffered saline, glucose, water, glycerol, ethanol, and combinations thereof.
[0375] In some embodiments, this disclosure provides pharmaceutical compositions comprising the RNAi active agent or RNAi conjugate of this disclosure (especially modified siRNA or siRNA conjugated to a GalNAc ligand) as the active ingredient and pharmaceutically acceptable diluents, carriers, and / or excipients (e.g., PBS buffer, physiological saline, water). The pharmaceutical compositions are intended to facilitate administration to a living organism, thereby promoting the absorption of the active ingredient and the exertment of its biological activity. Pharmaceutically acceptable diluents, carriers, and / or excipients as used in this disclosure include any suitable pharmaceutically acceptable diluents, carriers, and / or excipients known in the art.
[0376] In some embodiments, the RNAi active agent or RNAi conjugate according to this disclosure may be present in a non-buffered solution, preferably saline or water. In other embodiments, the RNAi active agent or RNAi conjugate according to this disclosure may be present in a buffered solution, preferably comprising acetate, citrate, alcohol-soluble gluten, carbonate, or phosphate, or any combination thereof; more preferably, the buffered solution is phosphate-buffered saline (PBS). In some embodiments, the RNAi active agent or RNAi conjugate according to this disclosure is formulated as a subcutaneous formulation. In other embodiments, the RNAi active agent or RNAi conjugate according to this disclosure is formulated as an intravenous formulation.
[0377] Application of RNAi activators
[0378] Pharmaceutical compositions comprising a C5 RNAi active agent or RNAi conjugate targeting C5 of this disclosure may be administered via a variety of suitable routes of administration, including but not limited to buccal, inhalation (including blowing or deep inhalation), nasal, oral, parenteral, implantation, injection, or infusion (via epidural, intra-articular, intra-articular, intracapsular, intracardiac, intracranial, intradermal, intramuscular, intraorbital, intraperitoneal, intraspinal, intrasternal, intrathecal, intravenous, subarachnoid, subcapsular, subcutaneous, subepidermal, transendothelial, transtracheal, transvascular, rectal, sublingual, local, and / or vaginal routes). Administration may be performed by injection, infusion, skin patch, or any other method known in the art. Formulations for administration may be powdered, atomized, aerosolized, granulated, or suitably prepared for delivery.
[0379] Pharmaceutical compositions comprising the C5 RNAi active agent or RNAi conjugate of this disclosure can be administered using medical devices known in the art. For example, in certain embodiments, the RNAi active agent can be administered using a needle-free subcutaneous injection device, such as those disclosed in U.S. Patent Nos. 5,399,163, 5,383,851, 5,312,335, 5,064,413, 4,941,880, 4,790,824, or 4,596,556. Examples of known implants and modules that can be used in the disclosure herein include: U.S. Patent No. 4,487,603, which discloses an implantable microinfusion pump for dispensing drugs at a controlled rate; U.S. Patent No. 4,486,194, which discloses a therapeutic device for administering drugs via the skin; U.S. Patent No. 4,447,233, which discloses a drug infusion pump for delivering drugs at a precise infusion rate; U.S. Patent No. 4,447,224, which discloses a variable-flow-rate implantable infusion device for continuous drug delivery; U.S. Patent No. 4,439,196, which discloses a permeable drug delivery system with multiple compartments; and U.S. Patent No. 4,475,196, which discloses a permeable drug delivery system. Many other such implants, delivery systems, and modules are known to those skilled in the art. In some embodiments, pharmaceutical compositions comprising the C5 RNAi active agent or RNAi conjugate of the present disclosure can be formulated to ensure proper distribution in vivo.
[0380] Treatment and prevention of C5-related diseases or conditions
[0381] This disclosure provides the use of the RNAi active agent or RNAi conjugate of this disclosure in the treatment or prevention of C5-related diseases or conditions, wherein a therapeutically effective amount or a preventatively effective amount of the RNAi active agent or RNAi conjugate of this disclosure is administered to human and non-human animal subjects in need. In this document, “C5-related disease or condition” means any disease involving dysfunction of C5 levels, expression, and / or activity, and / or any disease that can be treated and / or alleviated by regulating C5 levels, expression, and / or activity, such as age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, myasthenia gravis, immunoglobulin A nephropathy, atypical hemolytic uremic syndrome, and CHAPLE syndrome.
[0382] The RNAi active agents or RNAi conjugates targeting C5 described herein can be formulated into pharmaceutical compositions that can be administered to humans and non-human animals. These compositions may include one or more of the RNAi active agents or RNAi conjugates disclosed herein, and optionally other therapeutic agents for treating C5-related diseases. They may be administered as part of early / preventative treatment or may be administered at a therapeutically effective dose to treat individuals who have already presented with symptoms related to the said disease or condition. The administerable pharmaceutical compositions include those of any of the embodiments described above.
[0383] In some embodiments, the RNAi activator or RNAi conjugate used for this purpose may be any RNAi activator or any RNAi activator conjugate described in this disclosure. In some embodiments, the C5-related diseases or conditions include age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, and myasthenia gravis. In some embodiments, the C5-related diseases or conditions include immunoglobulin A nephropathy and atypical hemolytic uremic syndrome. In some embodiments, the C5-related diseases or conditions include CHAPLE syndrome, geographic atrophy, hemolysis, and neuromyelitis optica.
[0384] In some embodiments, this disclosure also provides a method for treating pathological conditions at least partially mediated or associated with C5 expression, the method comprising administering a therapeutically effective amount of the disclosed RNAi active agent or RNAi conjugate targeting C5 to a subject in need.
[0385] In some embodiments, the subject is a human being, and the RNAi active agent or RNAi conjugate is administered subcutaneously or intravenously.
[0386] In some embodiments, the RNAi activator according to this disclosure can be used to reduce C5 expression levels in cells (e.g., mammalian cells, such as human cells). In some embodiments, the RNAi activator according to this disclosure comprises at least 15, at least 16, at least 17, or at least 18 or more consecutive nucleotides targeting C5 mRNA. In some embodiments, the RNAi activator according to this disclosure comprises two oligonucleotide chains capable of forming a double-stranded region of at least 19 or more nucleotides. In some embodiments, the two oligonucleotide chains each comprise a sequence motif that differs from at least 18 consecutive nucleotides in the sense and antisense strand sequences of any of the RNAi molecules provided in Table 2 by 0, 1, 2, or 3 nucleotides. In some embodiments, each chain of the RNAi activator according to this disclosure has a length of less than 30 nucleotides, for example, 18-23 nucleotides and / or 19-21 nucleotides. In some embodiments, the double-stranded RNAi activator according to this disclosure may have one or two blunt ends or one or two overhangs, such as 3' and / or 5' overhangs of 1, 2, 3, or 4 nucleotides (i.e., 1-4 nt). The double-stranded RNAi activator according to this disclosure may also optionally contain one or two 5' and / or 3' end modifications (i.e., 5' caps and / or 3' caps) and / or one or more modified nucleotides. In some embodiments, the double-stranded RNAi activator according to this disclosure is an RNAi conjugate according to this disclosure, said conjugate comprising a GalNAc ligand according to this disclosure, particularly a monovalent, divalent, or trivalent GalNAc ligand having a P36 and / or L96 structure.
[0387] In some embodiments of the treatment and prevention provided in this disclosure, the subject is a mammal, such as a primate, rodent, or human. In some embodiments, administration of the disclosed GalNAc-siRNA or its pharmaceutical composition results in a decrease in serum C5 protein in the subject. It has been demonstrated that reducing serum C5 protein levels can effectively treat and / or prevent diseases or conditions caused by C5, including age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, myasthenia gravis, immunoglobulin A nephropathy, atypical hemolytic uremic syndrome, CHAPLE syndrome, geographic atrophy, hemolysis, and neuromyelitis optica.
[0388] The siRNA can be administered to the patient via any suitable route known in the art, including but not limited to: subcutaneous, intravenous, intramuscular, intrabronchial, intrapleural, intraperitoneal, intraarterial, lymphatic, and / or cerebrospinal fluid administration. The dosage of the RNAi reagents and compositions disclosed herein can be determined based on the patient's weight, age, sex, disease severity, etc. Subjects can be given therapeutic doses of siRNA, such as 0.05 mg / kg, 0.1 mg / kg, 0.2 mg / kg, 0.3 mg / kg, 0.4 mg / kg, 0.5 mg / kg, 1 mg / kg, 1.5 mg / kg, 2 mg / kg, 2.5 mg / kg body weight, etc. Dosing frequency can be based on regularity, such as daily, weekly, every two weeks, every three weeks, every month, every two months, every three months, every four months, every five months, every six months, every seven months, every eight months, every nine months, every ten months, every eleven months, annually, or for longer periods, with repeated administration. Following the initial treatment regimen, treatment can be administered at lower frequencies, for example, after monthly administration for three months, administration can continue for six months, one year, or longer. Administration of siRNA agents can reduce C5 protein levels in, for example, a patient's cells, tissues, blood, urine, or other compartments by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% or more.
[0389] abbreviation:
[0390] In describing RNAi activators in this disclosure, including Tables 2, 3, 6, 8-1, 8-2, A, and B of the above and the following examples, the following abbreviations are used:
[0391] Example
[0392] Example 1. Design of siRNA
[0393]
[0394] Table 2 hC5 siRNA
[0395] Note: In Table 2, SS represents the justice chain and AS represents the antisense chain.
[0396] Example 2. Preparation of modified siRNA
[0397] 1.1. Synthesis method of thio-modified siRNA
[0398] The modified hC5 siRNAs shown in Table 3 were synthesized using an oligonucleotide solid-phase synthesis process. Specifically, a universal solid-phase synthesis support (UnyLinker™ loaded HL Solid Supports, Kinovate Life Sciences) was used as the support, and phosphoramidite nucleoside monomers were used as starting materials. Nucleoside monomers were sequentially linked from the 3'-5' direction according to the oligonucleotide arrangement using the phosphoramidite solid-phase synthesis method. Then, ammonolysis was used to obtain crude oligonucleotides. After purification, ultrafiltration, and lyophilization, the crude product yielded two single-stranded oligonucleotides that constitute the siRNA. Finally, the two single-stranded oligonucleotides were annealed to form a double-stranded siRNA with reverse complementary base pairing.
[0399] The solid-phase synthesis process mainly consists of the following five steps (a, b, c, d, e). These five steps constitute one cycle; the cycle is repeated, and different types of nucleoside phosphoramide monomers are added sequentially according to the oligonucleotide sequence until the desired sequence is synthesized; the 5'-DMTr group at the end of the oligonucleotide is removed, and the cyanoethyl-protected phosphate is removed using a diethylamine acetonitrile solution (20% (v / v)). The solid-phase reaction ends, and an oligonucleotide single chain linked to a solid-phase support is obtained.
[0400] a. Deprotection reaction: Under room temperature conditions (20-25℃), the protecting group DMTr (dimethoxytriphenylmethyl) on the carrier / nucleotide is removed with dichloroacetic acid to obtain an active hydroxyl group that can undergo coupling reaction. The deprotecting reagent is a toluene solution of dichloroacetic acid (3% (v / v)) or a dichloromethane solution of dichloroacetic acid (3% (v / v)).
[0401] b. Coupling reaction: The nucleotide phosphoramidite monomer and the activator are simultaneously added to the solid-phase synthesis column. The phosphoramidite group is activated and undergoes a coupling condensation reaction with the active hydroxyl group to generate a phosphite triester. The activator is a 0.6M acetonitrile solution of 5-ethylthio-1H-tetrazole (ETT).
[0402] c. Oxidation reaction: Under the action of the oxidant iodine water, the triphosphite generated in the previous coupling condensation reaction is converted into a stable triphosphate. The oxidant is a 0.04M iodine / water / pyridine solution, v(water):v(pyridine) = 1:9.
[0403] d. Thio-reaction: Under the action of the thioreagent PADS / ADTT, the triphosphite generated by the coupling condensation in the previous step is converted into a stable thiophosphate ester; the reagent is 0.2M PADS (phenylacetyl disulfide), the solvent is 3-methylpyridine / acetonitrile 1:1, the reagent is 0.2M ADTT (hydroxanthin), the solvent is pyridine / acetonitrile 1:1.
[0404] e. Capping reaction: The active hydroxyl groups that have not fully reacted during the coupling reaction are capped to prevent them from participating in subsequent reactions. The capping reagents are CapA (acetic anhydride / acetonitrile) and CapB (NMI:Py:acetonitrile = 2:3:5).
[0405] The solid-phase support containing the above-mentioned oligonucleotides was subjected to ammonolysis using an ammonolysis reagent (25%–28% concentrated ammonia solution). This process cleaved and separated the oligonucleotides from the support while simultaneously removing various protecting groups from the nucleoside bases. The resulting solution was concentrated to obtain crude oligonucleotides. The crude product was sent for testing, and the target molecular weight was determined using high-resolution liquid chromatography-mass spectrometry (LC-MS).
[0406] The crude oligonucleotides were purified by anion exchange chromatography, followed by desalting using a gel column (HiTrap™ Desalting). The desalted sense and antisense strands were mixed in an equimolar ratio, heated to 55°C, held for 30 minutes, and then allowed to cool naturally to room temperature. The two single strands formed a double-stranded structure, siRNA, through hydrogen bonding. Molecular weight was determined using ion-pair reversed-phase chromatography (IPRP-HPLC) and high-resolution liquid chromatography-mass spectrometry (LC-MS) to confirm the preparation of the modified siRNAs shown in Table 3. All in vitro samples were purified by ion-pair reversed-phase chromatography, concentrated by vacuum centrifugation, reconstituted with water, and quantified using Nanodrop One. Annealing was performed after quantification. Each siRNA was analyzed by LC-MS to confirm its identity, quantified by UV (260 nm), and its purity was determined by HPLC.
[0407] Table 3. Sensitive and antisense strands contained in modified siRNAs
[0408] Note: If the first 6 digits of the ID of the modified compound in Table 3 are the same as the first 6 digits of the ID of the unmodified compound in Table 2, it means that the sequence motif of the modified compound in Table 3 is the same as the sequence motif of the corresponding unmodified compound in Table 2; the last 2 digits of the ID of the modified compound in Table 3 represent different modification forms of the corresponding unmodified compound in Table 2 (the same numbers do not necessarily mean the same modification form). For example, compound “BPR-99800201” in Table 3 is formed by introducing a modification on the sequence motif of compound “BPR-99800200” in Table 2; the bare AS sequence of BPR-99800102 in Table 3 is: UAUUAUAAAAAUAUCUUGCUUUUTT, SEQ ID NO:368.
[0409] Example 3. Activity detection of modified siRNA in liver cancer cells
[0410] 1. Cell Culture and Transfection
[0411] HepG2 liver cancer cell line was cultured in DMEM medium (source culture, L170KJ, batch number: M211137) containing 10% fetal bovine serum to near confluence at 37°C and 5% CO2. Cells were then released from the plate via trypsin digestion. 24 μL of Opti-MEM and 1 μL of siRNA or 1 μL of PBS control were added to an EP tube. In a new EP tube, 24.6 μL of Opti-MEM and 0.4 μL of Lipofectamine RNAiMax (Invitrogen, catalog number: 13778-150; batch number: CN2488100) were added. After incubation at room temperature for 5 minutes, the diluted RNAiMax from the EP tube was added to the diluted siRNA tube, gently mixed, and incubated at room temperature for 15-20 minutes. Then, 50 μL of transfection mixture was added to each well of a 96-well plate, followed by 150 μL of cell suspension to bring the final siRNA concentrations to 0.04 nM and 0.1 nM. Each well contained 20,000 cells and antibiotic-free Opti-MEM medium for reverse transfection. The negative control group consisted of cells transfected without siRNA (i.e., only PBS as the solvent), while the test group consisted of cells transfected with siRNA.
[0412] 2. RT-qPCR
[0413] After incubation at 37°C and 5% CO2 for 24 hours, transfected cells were subjected to cell lysis, RNA extraction, and RT-qPCR. RNA extraction was performed using an RNA extraction kit (Novizan, catalog number: RMA102-C1), and reverse transcription was performed using a HiScript III 1st Strand cDNA Synthesis Kit (+gDNA wiper) (vazyme, catalog number: R312-02, batch number: 027E2252CA), both performed according to the manufacturer's instructions.
[0414] qPCR was performed using Vazyme's AceQ qPCR Master Mix (catalog number: Q112-02, batch number: 027E2211KA) according to the manufacturer's instructions. 5 μL of the PCR mixture, 0.125 μL of 20x C5 probe primer mix, and 0.125 μL of 20x GAPDH probe primer mix were added to each well of a 384-well plate (Manad, catalog number: MQ50701S).
[0415] Next, add 2 μL of cDNA to each well and centrifuge to mix. Then, use qPCR to detect the expression levels of the target gene C5 and the internal reference gene GAPDH mRNA. Primer and probe information is shown below:
[0416] C5 primer and probe Mix (Thermo Fisher Scientific, 4351368)
[0417] GAPDH primer and probe Mix (Thermo Fisher Scientific, 4326317E).
[0418] Data Analysis: Ct(C5) values were automatically calculated using the default settings of Quant Studio 7 software. The Ct(C5) values were exported to an Excel file. The relative expression level of C5 mRNA was calculated using a 2-1 method. -ΔΔCt The calculation formula is as follows:
[0419] ΔCt(sample tested) = Ct(C5) – Ct(GAPDH),
[0420] ΔCt = ΔCt(sample) - ΔCt(NC)
[0421] C5 mRNA relative expression level = 2 -ΔΔCt
[0422] C5 mRNA relative inhibition rate (%) = (1 - C5 mRNA relative expression level) × 100%
[0423] 3. Results of in vitro screening of liver cancer cell activity
[0424] The results are shown in Tables 4 and 5: Most of the modified siRNAs in Table 3 showed inhibitory effects on C5 in HepG2, with inhibition rates of approximately 10%, 20%, 30%, 40%, 50%, 60%, 70%, and 80%.
[0425] Table 4. In vitro inhibition results of modified siRNA
[0426] Table 5. In vitro inhibition results of modified siRNA
[0427] Example 4: Preparation of modified siRNA
[0428] The modified siRNAs in Table 6 were synthesized according to the method described in Example 2.
[0429] Table 6 shows the sense and antisense strands contained in the modified siRNA.
[0430] Example 5: In vitro activity of modified siRNA
[0431] 1. Cell Culture and Transfection
[0432] At 37℃ and 5% CO 2 Under culture conditions, the HepG2 liver cancer cell line was cultured in DMEM medium (source culture, L170KJ, batch number: M211137) containing 10% fetal bovine serum until it reached near confluence. Cells were then released from the plate via trypsin digestion. 17 μL of Opti-MEM and 8 μL of siRNA (1 nM) or 0.4 μL of PBS control were added to an EP tube. In a new EP tube, 24.6 μL of Opti-MEM and 0.4 μL of Lipofectamine RNAiMax (Invitrogen, catalog number: 13778-150; batch number: CN2488100) were added and incubated at room temperature for 5 minutes. The diluted RNAiMax from the EP tube was then added to the diluted siRNA tube, gently mixed, and incubated at room temperature for 15–20 minutes. Finally, 50 μL of the transfection mixture was added to each well of a 96-well plate, followed by 150 μL of cell suspension to bring the final siRNA concentration to 0.1 nM. Each well contained 15,000 cells in an antibiotic-free Opti-MEM medium for reverse transfection; a negative control group was also set up that did not contain siRNA compounds (i.e., only the solvent PBS).
[0433] 2. RT-qPCR
[0434] After incubation at 37°C and 5% CO2 for 24 hours, transfected cells underwent cell lysis, RNA extraction, and RT-qPCR. RNA extraction was performed using an RNA extraction kit (Vazyme Medical, catalog number: FG0417-L, batch number: DK02A), and reverse transcription was performed using the HiScript III 1st Strand cDNA Synthesis Kit (+gDNA wiper) (vazyme, catalog number: R312-02, batch number: 027E2252CA), all according to the manufacturer's instructions.
[0435] qPCR was performed using Vazyme's AceQ qPCR Master Mix (catalog number: Q112-02, batch number: 027E2211KA) according to the manufacturer's instructions. 10 μL of the PCR mixture, 0.5 μL of 20x C5 probe primer mix, and 0.5 μL of 20x GAPDH probe primer mix were added to each well of a 96-well plate (Applied Bio Systems, catalog number: 4316813).
[0436] Next, add 5 μL of cDNA to each well, centrifuge with 4 μL of ddH2O to mix, and then perform qPCR to detect the expression levels of the target gene C5 and the internal reference gene GAPDH mRNA. Primer and probe information is shown below:
[0437] C5 primer and probe Mix (Thermo Fisher Scientific, 4351368)
[0438] GAPDH primer and probe Mix (Thermo Fisher Scientific, 4326317E).
[0439] Data Analysis: Ct(C5) values were automatically calculated using the default settings of Quant Studio 7 software. The Ct(C5) values were exported to an Excel file. The relative expression level of C5 mRNA was calculated using a 2-1 method. -ΔΔCT The calculation formula is as follows:
[0440] ΔCt(sample tested) = Ct(C5) – Ct(GAPDH),
[0441] ΔCt = ΔCt(sample) - ΔCt(NC)
[0442] C5 mRNA relative expression level = 2 -ΔΔCT
[0443] C5 mRNA relative inhibition rate (%) = (1 - C5 mRNA relative expression level) × 100%
[0444] 3. Results of in vitro screening of liver cancer cell activity
[0445] Table 6 of Example 4 shows the inhibition results of the modified siRNA at a HepG2 concentration of 0.1 nM, as shown in Table 7.
[0446] Table 7. In vitro inhibitory effect of modified siRNA
[0447] The results in Table 7 show that most of the modified siRNAs in Table 6 have an inhibitory effect on C5 in HepG2, with inhibition rates of approximately 10%, 20%, 30%, 40%, 50%, 60%, 70%, and 80%.
[0448] Example 6: Drug efficacy evaluation in humanized mice
[0449] In this study, a single subcutaneous injection of the drug composition into humanized C5 mice (hC5, Youji (Tianjin) Pharmaceutical Technology Co., Ltd.) was administered to investigate its ability to inhibit C5 gene expression in vivo. Male mice aged 6-8 weeks were introduced into the facility for acclimatization at least one week in advance. Blood samples (as pre-drug administration) and serum C5 protein levels were measured during the acclimatization period. After acclimatization, the mice were randomly assigned to groups of 5 animals each based on body weight and pre-drug serum C5 protein levels. Single-dose subcutaneous injections of BPR-99812568.1, BPR-99811307.1, BPR-99811308.1, BPR-99811309.1, BPR-99811310.1, BPR-99811123.1, and BPR-99811675.1 at a dose of 10 μl / g per mouse were administered. The control group received an equal volume of physiological saline. Day 0 was the day of administration. Blood samples were collected at different time points: Day 7, Day 14, Day 21, Day 28, and Day 35, with a blood volume of approximately 100 μL. Serum was obtained after centrifugation. Serum C5 protein was quantified using an ELISA kit (Human Complement C5 ELISA Kit 1033329-19 / 20 Abcam), following the kit's instructions. The formula for calculating the relative inhibition rate of serum C5 protein at each time point after drug administration in each animal is: 100% * (C5 serum protein content at each time point after drug administration / corresponding individual's pre-drug C5 serum protein content - 1). The sequence information of the modified siRNA in the siRNA conjugate is shown in Table 8-1, and the sequence information of the siRNA conjugate is shown in Table 8-2.
[0450] Table 8-1 Sequence information of modified siRNAs in siRNA conjugates
[0451] Table 8-2 Sequence information of siRNA conjugates
[0452] As shown in Figure 1, the conjugates BPR-99812568.1, BPR-99811310.1, BPR-99811123.1, and BPR-99811675.1 all inhibited the expression of mouse C5 protein.
Claims
1. An RNAi activator for inhibiting C5 expression, wherein the RNAi activator comprises an antisense strand and a sense strand forming a double-stranded region. in: The antisense strand comprises a nucleotide sequence complementary to at least 15 consecutive nucleotides in a human C5 mRNA fragment, or a nucleotide sequence differing from said nucleotide sequence by no more than 3, 2, or 1 nucleotide; and optionally, the sense strand comprises a nucleotide sequence identical to at least 15 consecutive nucleotides in the corresponding mRNA fragment or differing from said nucleotide sequence by no more than 3, 2, or 1 nucleotide. The human C5 mRNA fragments mentioned therein are selected from the fragments corresponding to nucleotide positions 182-230, 749-808, 845-912, 984-1009, 1504-1530, 1884-1910 or 1979-2026 of SEQ ID NO:367; Preferably, the antisense strand comprises a nucleotide sequence complementary to at least 16, 17, 18, 19, 20, 21, 22, or 23 consecutive nucleotides in a human C5 mRNA fragment, or a nucleotide sequence differing from said nucleotide sequence by no more than 3, 2, or 1 nucleotide; and optionally, the sense strand comprises a nucleotide sequence identical to or differing from at least 16, 17, 18, 19, 20, or 21 consecutive nucleotides in the corresponding mRNA fragment by no more than 3, 2, or 1 nucleotide. Preferably, the antisense strand contains a sequence motif, which comprises at least 15 consecutive nucleotides of any antisense strand shown in Table 2, or a sequence motif that differs from the sequence motif by no more than 3, 2, or 1 nucleotides. Preferably, the antisense strand comprises a sequence motif, which comprises at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22 or at least 23 consecutive nucleotides of any antisense strand shown in Table 2, or a sequence motif that differs from the sequence motif by no more than 3, 2 or 1 nucleotides. Preferably, the positive strand contains a sequence motif, which comprises at least 15 consecutive nucleotides of any positive strand shown in Table 2, or a sequence motif that differs from the sequence motif by no more than 3, 2, or 1 nucleotides. Preferably, the positive strand contains a sequence motif comprising at least 16, 17, 18, 19, 20, or 21 consecutive nucleotides of any positive strand shown in Table 2, or a sequence motif differing from the sequence motif by no more than 3, 2, or 1 nucleotides.
2. The RNAi activator according to claim 1, wherein the antisense strand comprises a sequence motif, the sequence motif comprising at least 15 consecutive nucleotides selected from any nucleotide sequence of SEQ ID NO: 10, 14, 18, 20, 22, 24, 46, 72, 82, 84, 114, 130, 134, 138, 200, 222, 226, 232, 234, 236, 250, 254, 268, 328, 362 or 366, or a sequence motif differing from the sequence motif by no more than 3, 2 or 1 nucleotides; Preferably, the antisense strand comprises a sequence motif comprising at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 consecutive nucleotides selected from any of the nucleotide sequences chosen from SEQ ID NO: 10, 14, 18, 20, 22, 24, 46, 72, 82, 84, 114, 130, 134, 138, 200, 222, 226, 232, 234, 236, 250, 254, 268, 328, 362, or 366, or a sequence motif differing from the sequence motif by no more than 3, 2, or 1 nucleotides. Preferably, the positive strand comprises a sequence motif comprising at least 15 consecutive nucleotides selected from any nucleotide sequence of SEQ ID NO: 9, 13, 17, 19, 21, 23, 45, 71, 81, 83, 113, 129, 133, 137, 199, 221, 225, 231, 233, 235, 249, 253, 267, 327, 361, or 365, or a sequence motif differing from the sequence motif by no more than 3, 2, or 1 nucleotides. Preferably, the positive strand comprises a sequence motif comprising at least 16, at least 17, at least 18, at least 19, at least 20, or at least 21 consecutive nucleotides selected from any of the nucleotide sequences selected from SEQ ID NO: 9, 13, 17, 19, 21, 23, 45, 71, 81, 83, 113, 129, 133, 137, 199, 221, 225, 231, 233, 235, 249, 253, 267, 327, 361, or 365, or a sequence motif differing from the sequence motif by no more than 3, 2, or 1 nucleotides.
3. The RNAi activator according to any one of claims 1 or 2, wherein the antisense strand comprises a sequence motif, the sequence motif comprising at least 15 consecutive nucleotides selected from any nucleotide sequence selected from SEQ ID NO: 10, 14, 18, 22, 24, 72, 82, 84, 114, 130, 134, 200, 222, 226, 232, 234, 236, 250, 254 or 268, or a sequence motif differing from the sequence motif by no more than 3, 2 or 1 nucleotides; Preferably, the antisense strand comprises a sequence motif comprising at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 consecutive nucleotides selected from any of the nucleotide sequences chosen from SEQ ID NO: 10, 14, 18, 22, 24, 72, 82, 84, 114, 130, 134, 200, 222, 226, 232, 234, 236, 250, 254, or 268, or a sequence motif differing from the sequence motif by no more than 3, 2, or 1 nucleotides. Preferably, the positive strand comprises a sequence motif comprising at least 15 consecutive nucleotides selected from any nucleotide sequence of SEQ ID NO: 9, 13, 17, 21, 23, 71, 81, 83, 113, 129, 133, 199, 221, 225, 231, 233, 235, 249, 253 or 267, or a sequence motif differing from the sequence motif by no more than 3, 2 or 1 nucleotides. Preferably, the positive strand comprises a sequence motif comprising at least 16, at least 17, at least 18, at least 19, at least 20, or at least 21 consecutive nucleotides selected from any of the nucleotide sequences chosen from SEQ ID NO: 9, 13, 17, 21, 23, 71, 81, 83, 113, 129, 133, 199, 221, 225, 231, 233, 235, 249, 253, or 267, or a sequence motif differing from the sequence motif by no more than 3, 2, or 1 nucleotides. Preferably, the antisense strand comprises a sequence motif, the sequence motif comprising at least 15 consecutive nucleotides selected from any nucleotide sequence of SEQ ID NO: 222, 226, 232 or 250, or a sequence motif differing from the sequence motif by no more than 3, 2 or 1 nucleotides; Preferably, the antisense strand comprises a sequence motif comprising at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 consecutive nucleotides selected from any nucleotide sequence of SEQ ID NO: 222, 226, 232, or 250, or a sequence motif differing from the sequence motif by no more than 3, 2, or 1 nucleotides. Preferably, the positive strand comprises a sequence motif, the sequence motif comprising at least 15 consecutive nucleotides selected from any nucleotide sequence of SEQ ID NO: 221, 225, 231 or 249, or a sequence motif differing from the sequence motif by no more than 3, 2 or 1 nucleotides; Preferably, the positive strand comprises a sequence motif comprising at least 16, at least 17, at least 18, at least 19, at least 20, or at least 21 consecutive nucleotides selected from any nucleotide sequence of SEQ ID NO: 221, 225, 231, or 249, or a sequence motif differing from the sequence motif by no more than 3, 2, or 1 nucleotides.
4. The RNAi activator according to any one of claims 1-3, wherein the RNAi activator comprises a protruding end; Preferably, the antisense strand and / or the sense strand includes a 5' overhang and / or a 3' overhang of at least one nucleotide; Preferably, the antisense strand and / or the sense strand includes a 3' overhang of at least one nucleotide; Preferably, the overhang is a 3' overhang composed of 1, 2, 3, or 4 nucleotides from the 3' end of the antisense strand; Preferably, the overhang is a 3' overhang composed of two nucleotides from the 3' end of the antisense strand; Preferably, the RNAi activator does not contain protruding ends; Preferably, the antisense strand and the sense strand each independently contain 15 to 35 nucleotides, more preferably 17 to 35 nucleotides; Preferably, the antisense strand contains 18 to 30 nucleotides. Preferably, the antisense strand contains 19 to 25 nucleotides; Preferably, the positive chain contains 18 to 27 nucleotides; Preferably, the positive chain contains 19 to 22 nucleotides; Preferably, the antisense strand and the sense strand form a double-stranded region of 15-35, 17-35, 15-30, 17-30, 15-23, 17-23, 19-35, 19-30, 19-27, 19-25, or 19-23 nucleotide pairs in length; Preferably, the double-stranded region comprises 19-23 nucleotide pairs; Preferably, the antisense chain and the justice chain are completely complementary or substantially complementary in the bisense region; Preferably, the antisense strand is 23 nucleotides long, the sense strand is 21 nucleotides long, and the double-stranded region is 21 nucleotide pairs long.
5. The RNAi activator according to any one of claims 1-4, wherein the sense strand and antisense strand of the RNAi activator respectively comprise the sequence motifs of the sense strand and antisense strand of any siRNA shown in Table 2, or sequence motifs that differ from the sequence motifs of the sense strand and antisense strand of any siRNA shown in Table 2 by no more than 3, 2, or 1 nucleotides respectively. Preferably, the sense and antisense strands of the RNAi activator each contain the following sequence motifs, or nucleotide sequences differing from them by no more than 3, 2, or 1 nucleotide: a1) Nucleotide sequences as shown in SEQ ID NO:9 and SEQ ID NO:10; a2) Nucleotide sequences as shown in SEQ ID NO:13 and SEQ ID NO:14; a3) Nucleotide sequences as shown in SEQ ID NO:17 and SEQ ID NO:18; a4) Nucleotide sequences as shown in SEQ ID NO:19 and SEQ ID NO:20; a5) Nucleotide sequences as shown in SEQ ID NO:21 and nucleotide sequences as shown in SEQ ID NO:22; a6) Nucleotide sequences as shown in SEQ ID NO:23 and SEQ ID NO:24; a7) Nucleotide sequences as shown in SEQ ID NO:45 and SEQ ID NO:46; a8) Nucleotide sequences as shown in SEQ ID NO:71 and nucleotide sequences as shown in SEQ ID NO:72; a9) Nucleotide sequences as shown in SEQ ID NO:81 and nucleotide sequences as shown in SEQ ID NO:82; a10) Nucleotide sequences as shown in SEQ ID NO:83 and SEQ ID NO:84; a11) Nucleotide sequences as shown in SEQ ID NO:113 and nucleotide sequences as shown in SEQ ID NO:114; a12) Nucleotide sequences as shown in SEQ ID NO:129 and nucleotide sequences as shown in SEQ ID NO:130; a13) Nucleotide sequences as shown in SEQ ID NO:133 and SEQ ID NO:134; a14) Nucleotide sequences as shown in SEQ ID NO:137 and SEQ ID NO:138; a15) Nucleotide sequences as shown in SEQ ID NO:199 and SEQ ID NO:200; a16) Nucleotide sequences as shown in SEQ ID NO:221 and nucleotide sequences as shown in SEQ ID NO:222; a17) Nucleotide sequences as shown in SEQ ID NO:225 and SEQ ID NO:226; a18) Nucleotide sequences as shown in SEQ ID NO:231 and nucleotide sequences as shown in SEQ ID NO:232; a19) Nucleotide sequences as shown in SEQ ID NO:233 and SEQ ID NO:234; a20) Nucleotide sequences as shown in SEQ ID NO:235 and SEQ ID NO:236; a21) Nucleotide sequences as shown in SEQ ID NO:249 and SEQ ID NO:250; a22) Nucleotide sequences as shown in SEQ ID NO:253 and SEQ ID NO:254; a23) Nucleotide sequences as shown in SEQ ID NO:267 and SEQ ID NO:268; a24) Nucleotide sequences as shown in SEQ ID NO:327 and SEQ ID NO:328; a25) Nucleotide sequences as shown in SEQ ID NO:361 and nucleotide sequences as shown in SEQ ID NO:362; or a26) Nucleotide sequences as shown in SEQ ID NO:365 and SEQ ID NO:366; Preferably, the sense and antisense strands of the RNAi activator respectively contain any of the sequence motifs shown in a1)-a3), a5)-a6), a8)-a13), a15)-a23), or nucleotide sequences that differ from it by no more than 3, 2 or 1 nucleotides; Preferably, the sense and antisense strands of the RNAi activator contain sequence motifs shown in any of a16)-a18) and a21), or nucleotide sequences that differ from it by no more than 3, 2 or 1 nucleotides.
6. The RNAi activator according to any one of claims 1-5, wherein each nucleotide in the sense strand is independently a modified nucleotide or an unmodified nucleotide, and / or each nucleotide in the antisense strand is independently a modified nucleotide or an unmodified nucleotide. Preferably, the RNAi activator contains modifications on the sense strand, antisense strand, or both, including nucleoside base modifications, nucleoside sugar ring modifications, inter-nucleoside linkage modifications, or any combination thereof; Preferably, the modified nucleotide is selected from one or more of the following: 2'-O-methyl modified nucleotide, 2'-fluoro modified nucleotide, 2'-deoxy modified nucleotide, 2'-O-methoxyethyl modified nucleotide, 2'-amino modified nucleotide, 2'-alkoxy modified nucleotide, phosphate thioester modified nucleotide, locked nucleotide, 2',3'-broken nucleotide, debaseted nucleotide, L-2'-fluoro modified nucleotide, L-2'-O-methyl modified nucleotide, L-2'-deoxyribonucleotide, threononucleotide, 4'-modified threononucleotide, glycol-modified nucleotide, reverse nucleotide, reverse 2'-O-methyl modified nucleotide, reverse 2'-deoxyribonucleotide, 5'-vinyl phosphate nucleotide; Preferably, the modified nucleotide is selected from one or more of the following: 2'-deoxy modified nucleotide, 2'-fluoro modified nucleotide, 2'-O-methyl modified nucleotide, 2'-O-methoxyethyl modified nucleotide, phosphate thioester modified nucleotide, 4'-modified threonine nucleic acid, and glycol nucleic acid; Preferably, the modified nucleotide is selected from one or more of the following: 2'-O-methyl modified nucleotide, 2'-fluoro modified nucleotide, 2'-deoxyribonucleotide, and 2'-O-methoxyethyl modified nucleotide.
7. The RNAi activator according to any one of claims 1-6, wherein, At least 50% of the nucleotides in the RNAi activator are 2'-O-methyl modified nucleotides, 2'-fluoro modified nucleotides, 2'-O-methoxyethyl modified nucleotides, and / or 2'-deoxyribonucleotides. Preferably, each nucleotide in the sense strand and the antisense strand is independently selected from 2'-O-methyl modified nucleotides, 2'-fluoro modified nucleotides, 2'-O-methoxyethyl modified nucleotides, and / or 2'-deoxyribonucleotides; Preferably, each nucleotide in the sense strand and the antisense strand is independently selected from: b1) nucleotides modified with 2'-O-methyl and nucleotides modified with 2'-fluorine; b2) 2'-deoxyribonucleotides, 2'-O-methyl modified nucleotides, and 2'-fluoro modified nucleotides; or b3) nucleotides modified with 2'-O-methoxyethyl, 2'-deoxyribonucleotides, 2'-O-methyl, and 2'-fluoronucleotides; Preferably, along the 5' to 3' direction, c1) The nucleotides at positions 1, 2, 4, 6, 8, 12, 14, 15, 17, 19, 20 and 21 of the positive strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine. c2) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20 and 21 of the positive strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine. c3) The nucleotides at positions 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 15, 16, 17, 18, 19, 20 and 21 of the positive strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine. c4) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20 and 21 of the positive strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 10 is a 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine. c5) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20 and 21 of the positive strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 9 is a 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine. c6) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20 and 21 of the positive strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 11 is a 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine. c7) The nucleotides at positions 1, 2, 3, 4, 5, 6, 7, 8, 12, 14, 15, 16, 17, 18, 19, 20 and 21 of the positive strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 10 is a 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine. c8) The nucleotides at positions 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 15, 17, 18, 19, 20 and 21 of the positive strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine. c9) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 17, 18, 19, 20, and 21 of the positive strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 10 is a 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluoronucleotides; or c10) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20 and 21 of the positive strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 7 and 10 are nucleotides modified with 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine. Preferably, along the 5' to 3' direction, d1) The nucleotides at positions 1, 4, 6, 7, 9, 11, 12, 13, 15, 17, 19, 20, 21, 22 and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine. d2) The nucleotides at positions 1, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22 and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine. d3) The nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22 and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5 and 7 are nucleotides modified with 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine. d4) The nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5 and 7 are nucleotides modified with 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluoronucleotide; d5) The nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 12, 13, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5 and 7 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotide at position 15 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluoro. d6) The nucleotides at positions 1, 4, 5, 7, 8, 9, 10, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 2 is a nucleotide modified with 2'-deoxyribonucleotide, the nucleotide at position 3 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluoro. d7) The nucleotides at positions 1, 5, 7, 8, 9, 10, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 2 and 4 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotide at position 3 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluoro. d8) The nucleotides at positions 1, 3, 4, 5, 7, 8, 9, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 12 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluoro. d9) The nucleotides at positions 1, 3, 4, 5, 7, 8, 9, 10, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 11 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluoro. d10) The nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22 and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 5 is a 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine. d11) The nucleotides at positions 1, 3, 4, 8, 9, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22 and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5 and 7 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotide at position 6 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluoro. d12) The nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 12 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotide at position 15 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluoro. d13) The nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 16, 17, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 18 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotides at positions 12 and 15 are nucleotides modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluoro. d14) The nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 16 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotide at position 15 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluoro. d15) The nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 2, 5, and 7 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotide at position 15 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluoro. d16) The nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 14 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotide at position 15 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluoro. d17) The nucleotides at positions 1, 3, 4, 6, 8, 10, 11, 13, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 9 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotides at positions 12 and 15 are nucleotides modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluoro. d18) The nucleotides at positions 1, 3, 4, 6, 8, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 9 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotide at position 12 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluoro. d19) The antisense strand is composed of nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 17, 18, 19, 21, 22, and 23 that are 2'-O-methyl modified nucleotides, nucleotides at positions 5, 7, and 20 that are 2'-deoxyribonucleotides, nucleotides at positions 12 and 15 that are 2'-O-methoxyethyl modified nucleotides, and nucleotides at the remaining positions that are 2'-fluoro modified nucleotides; or d20) The nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 15, 17, 18, 19, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 20 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotide at position 12 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluoro. Preferably, along the 5' to 3' direction, f1) The nucleotides at positions 1, 2, 4, 6, 8, 12, 14, 15, 17, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 4, 6, 7, 9, 11, 12, 13, 15, 17, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine. f2) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine. f3) The nucleotides at positions 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5 and 7 are nucleotides modified with 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine. f4) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5 and 7 are nucleotides modified with 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine. f5) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 12, 13, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5 and 7 are 2'-deoxyribonucleotides, the nucleotide at position 15 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine. f6) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 4, 5, 7, 8, 9, 10, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 2 is a 2'-deoxyribonucleotide, the nucleotide at position 3 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine. f7) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 5, 7, 8, 9, 10, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 2 and 4 are 2'-deoxyribonucleotides, the nucleotide at position 3 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine. f8) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 10 is a 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 5, 7, 8, 9, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 12 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine. f9) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 9 is a 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 5, 7, 8, 9, 10, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 11 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine. f10) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 11 is a 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine; The nucleotides at positions 1, 3, 4, 5, 7, 8, 9, 10, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 11 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine. f11) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 5 is a 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine. f12) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 8, 9, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5 and 7 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotide at position 6 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine. f13) The nucleotides at positions 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 12 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotide at position 15 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine. f14) The nucleotides at positions 1, 2, 3, 4, 5, 6, 7, 8, 12, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 10 is a 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 16, 17, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 18 are 2'-deoxyribonucleotides, the nucleotides at positions 12 and 15 are nucleotides modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine. f15) The nucleotides at positions 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 15, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 16 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotide at position 15 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine. f16) The nucleotides at positions 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 15, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 2, 5, and 7 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotide at position 15 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine. f17) The nucleotides at positions 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 14 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotide at position 15 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine. f18) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 10 is a 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 6, 8, 10, 11, 13, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 9 are 2'-deoxyribonucleotides, the nucleotides at positions 12 and 15 are nucleotides modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine. f19) The nucleotides at positions 1, 2, 3, 4, 5, 6, 7, 8, 12, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 10 is a 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 6, 8, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 9 are 2'-deoxyribonucleotide, the nucleotide at position 12 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine. f20) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are 2'-O-methyl modified nucleotides, the nucleotides at positions 7 and 10 are 2'-deoxyribonucleotides, and the remaining positions are 2'-fluoro modified nucleotides; the nucleotides at positions 1, 3, 4, 6, 8, 10, 11, 13, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are 2'-O-methyl modified nucleotides, the nucleotides at positions 5, 7, and 9 are 2'-deoxyribonucleotides, the nucleotides at positions 12 and 15 are 2'-O-methoxyethyl modified nucleotides, and the remaining positions are 2'-fluoro modified nucleotides; f21) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 10 is a 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 17, 18, 19, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 20 are 2'-deoxyribonucleotides, the nucleotides at positions 12 and 15 are nucleotides modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine. f22) The nucleotides at positions 1, 2, 3, 4, 5, 6, 7, 8, 12, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, the nucleotide at position 10 is a 2'-deoxyribonucleotide, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 15, 17, 18, 19, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 20 are 2'-deoxyribonucleotide, the nucleotide at position 12 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine. f23) The nucleotides at positions 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are 2'-O-methyl modified nucleotides, the nucleotides at positions 7 and 10 are 2'-deoxyribonucleotides, and the remaining positions are 2'-fluoro modified nucleotides; the nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 17, 18, 19, 21, 22, and 23 of the antisense strand are 2'-O-methyl modified nucleotides, the nucleotides at positions 5, 7, and 20 are 2'-deoxyribonucleotides, the nucleotides at positions 12 and 15 are 2'-O-methoxyethyl modified nucleotides, and the remaining positions are 2'-fluoro modified nucleotides; f24) The nucleotides at positions 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 12 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotide at position 15 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine. f25) The nucleotides at positions 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 15, 16, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 14 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotide at position 15 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine. f26) The nucleotides at positions 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 15, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 5, 7, and 16 are 2'-deoxyribonucleotides, the nucleotide at position 15 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine; or f27) The nucleotides at positions 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 15, 17, 18, 19, 20, and 21 of the sense strand are nucleotides modified with 2'-O-methyl, and the remaining positions are nucleotides modified with 2'-fluorine; the nucleotides at positions 1, 3, 4, 6, 8, 9, 10, 11, 13, 17, 18, 19, 20, 21, 22, and 23 of the antisense strand are nucleotides modified with 2'-O-methyl, the nucleotides at positions 2, 5, and 7 are nucleotides modified with 2'-deoxyribonucleotide, the nucleotide at position 15 is a nucleotide modified with 2'-O-methoxyethyl, and the remaining positions are nucleotides modified with 2'-fluorine.
8. The RNAi activator according to any one of claims 1-7, wherein the RNAi activator comprises at least 0-3 phosphate thioester or methyl phosphate linkages; Preferably, the RNAi activator comprises at least one phosphate thioester or methyl phosphate linker; Preferably, the antisense strand and the sense strand each contain 0, 1, 2 or 3 thiophosphate links at the 5' end and / or the 3' end, respectively; Preferably, the RNAi activator has at least one or at least two phosphate thioester nucleotide bonds at the first five nucleotides counted from the 5' end of the antisense strand; Preferably, the RNAi activator has one or two phosphate thioester nucleotide bonds at the first five nucleotides counting from the 3' end of the antisense strand; Preferably, the RNAi activator has at least one or at least two phosphate thioester nucleotide bonds at the first five nucleotides counted from the 5' end of the positive strand; Preferably, the RNAi activator has at least one or at least two phosphate thioester nucleotide bonds at the first five nucleotides counted from the 3' end of the positive strand; Preferably, the antisense chain comprises two thiophosphate links at the 5' end and the 3' end, respectively; and / or The positive chain contains 0, 1, and 2 thiophosphate linkages at the 5' and 3' ends, respectively; Preferably, the RNAi activator has phosphate-thioester nucleotide bonds between the first and second nucleotides and between the second and third nucleotides, counting from the 5' end of the antisense strand; and the RNAi activator has phosphate-thioester nucleotide bonds between the first and second nucleotides and between the second and third nucleotides, counting from the 3' end of the antisense strand; and / or The RNAi activator has phosphate-thionucleotide bonds between the first and second nucleotides and between the second and third nucleotides, counting from the 5' end of the positive strand.
9. The RNAi activator according to any one of claims 1-8, wherein the antisense strand of the RNAi activator comprises: a sequence motif of at least 18, at least 19, at least 20, at least 21, at least 22 or at least 23 consecutive nucleotides of any antisense strand shown in Table 3, Table 6 or Table 8-1, or a sequence motif differing from the sequence motif by no more than 3, 2 or 1 nucleotides; Preferably, the positive strand of the RNAi activator comprises: a sequence motif of at least 17, at least 18, at least 19, at least 20, or at least 21 consecutive nucleotides of any positive strand shown in Table 3, Table 6, or Table 8-1, or a sequence motif that differs from the sequence motif by no more than 3, 2, or 1 nucleotides. Preferably, the antisense strand of the RNAi activator comprises: a sequence motif of at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 consecutive nucleotides of any antisense strand shown in Table A or Table B, or a sequence motif that differs from the sequence motif by no more than 3, 2, or 1 nucleotides. Preferably, the positive strand of the RNAi activator comprises: a sequence motif of at least 17, at least 18, at least 19, at least 20, or at least 21 consecutive nucleotides of any positive strand shown in Table A or Table B, or a sequence motif that differs from the sequence motif by no more than 3, 2, or 1 nucleotides.
10. The RNAi activator according to any one of claims 1-9, wherein the RNAi activator comprises the sense and antisense strands of any siRNA selected from those shown in Table 3, Table 6, or Table 8-1; Preferably, the RNAi activator comprises the sense and antisense strands of any siRNA selected from those shown in Table A or Table B.
11. An RNAi conjugate comprising the RNAi activator according to any one of claims 1-10.
12. The RNAi conjugate of claim 11, wherein the conjugation of the RNAi conjugate occurs at the 5' and / or 3' end of the sense strand and optionally the 3' end of the antisense strand of the RNAi activator, optionally, the conjugation is performed via thiophosphate group linkage or phosphate group linkage.
13. The RNAi conjugate according to any one of claims 11-12, wherein the RNAi activator is conjugated with an antibody, peptide, peptide mimic, aptamer, small chemical compound, lipid, cell-penetrating peptide polymer or nanoparticle.
14. The RNAi conjugate according to any one of claims 11-13, wherein the RNAi activator is conjugated to an asialic acid glycoprotein receptor (ASGPR) ligand.
15. The RNAi conjugate of claim 14, wherein the ASGPR ligand comprises one or more N-acetylgalactosamine (GalNAc) or derivative thereof; Preferably, the ASGPR ligand comprises a monovalent, bivalent, trivalent, or tetravalent ASGPR ligand; Preferably, the ASGPR ligand is selected from monovalent, divalent, trivalent, or tetravalent GalNAc ligands; Preferably, the RNAi conjugate has the following structure: M-(ON), where ON represents the oligonucleotide duplex of the RNAi activator, M represents the trivalent GalNAc ligand, and "-" indicates that the trivalent GalNAc ligand is chemically coupled to the oligonucleotide duplex or coupled with a linker group; preferably, M is attached to the 3' end of the positive strand of the RNAi activator. Preferably, the trivalent GalNAc ligand has the following structure: More preferably, the RNAi conjugate has the structure shown in the following formula: in The term represents the double-stranded oligonucleotide of the RNAi, where 3' represents the 3' end of the sense strand, and X is O or S; Preferably, the RNAi conjugate is selected from any conjugate in Table B or Table 8-2.
16. A composition comprising an RNAi activator according to any one of claims 1-10 or an RNAi conjugate according to any one of claims 11-15 and optionally a pharmaceutically acceptable diluent, carrier, and / or excipient; preferably, the diluent is PBS buffer, physiological saline, or water; or The RNAi reagent or conjugate is present in a buffer solution, preferably comprising acetate, citrate, alcohol-soluble gluten, carbonate, or phosphate, or any combination thereof, more preferably, the buffer solution is phosphate-buffered saline (PBS).
17. A pharmaceutical combination comprising an RNAi activator according to any one of claims 1-10, an RNAi conjugate according to any one of claims 11-15, or a composition according to claim 16, and one or more other therapeutic agents, said other therapeutic agents being any therapeutic agent effective in preventing or treating diseases or conditions mediated or associated with C5.
18. A method for inhibiting C5 gene expression in cells, wherein the method comprises delivering an RNAi activator according to any one of claims 1-10, an RNAi conjugate according to any one of claims 11-15, a composition according to claim 16, or a pharmaceutical combination according to claim 17 to the cells, thereby inhibiting C5 gene expression in the cells, optionally, the cells being in vitro or ex vivo cells, preferably, the cells being human cells or monkey cells.
19. The use of the RNAi activator according to any one of claims 1-10, the conjugate according to any one of claims 11-15, the composition according to claim 16, or the pharmaceutical combination according to claim 17 as a medicament or in the preparation of a medicament, preferably, wherein the medicament is used to reduce C5 levels and / or expression in a subject, or to prevent or treat diseases or conditions mediated or associated with C5. Preferably, the disease or condition is selected from: age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, myasthenia gravis, immunoglobulin A nephropathy, atypical hemolytic uremic syndrome, CHAPLE syndrome, geographic atrophy, hemolysis, and neuromyelitis optica.
20. A method for preventing or treating a disease or condition mediated or associated with C5, wherein the method comprises administering to a subject in need a therapeutically effective amount of the RNAi active agent according to any one of claims 1-10, the conjugate according to any one of claims 11-15, the composition according to claim 16, or the pharmaceutical combination according to claim 17; Preferably, the disease or condition is selected from: age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, myasthenia gravis, immunoglobulin A nephropathy, atypical hemolytic uremic syndrome, CHAPLE syndrome, geographic atrophy, hemolysis, and neuromyelitis optica.
